ARRDC1-MEDIATED MICROVESICLE (ARMMS) DEGRADATION SYSTEM AND USES THEREOF
Patent Information
- Application Number
- JP2024534232
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-09
- Filing Date
- 2022-12-08
- Publication Date
- 2024-12-05
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 2024545120000001_ABST
Abstract
Description
[Technical field]
[0001] Related Articles This application is entitled to and claims the benefit of the filing date of U.S. Provisional Patent Application No. 63 / 287,683, filed December 9, 2021. [Background technology]
[0002] Protein degradation is a highly regulated process that maintains cellular homeostasis. The ubiquitin-proteasome pathway (UPP) is a common pathway for protein degradation in eukaryotic cells. Numerous cellular pathways are controlled by the UPP mechanism, including antigen processing, apoptosis, organelle biogenesis, cell cycle, DNA transcription and repair, differentiation and development, immune response and inflammation, nerve and muscle degeneration, neural network morphogenesis, modulation of cell surface receptors, ion channels and secretory pathways, response to stress and extracellular modulators, ribosome biogenesis and viral infection. Protein degradation via the UPP involves two steps: the first step is tagging of substrates by covalent attachment of multiple ubiquitin molecules, and the second step is degradation of the tagged proteins by the 26S proteasome complex with the release of liberable and reusable ubiquitin. E3 ubiquitin ligases play a key role in the UPP, determining substrate specificity and covalently attaching multiple ubiquitin molecules to terminal lysine residues of substrate proteins. The UPP can reduce the expression of cellular proteins without the need for genome modification, and there is a need to develop new UPP-mediated targeted protein degradation systems. Summary of the Invention
[0003] Provided herein is an arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicle (ARMM) containing a degradation system and uses thereof. In particular, provided herein is an ARRDC1 fusion protein comprising an ARRDC1 protein or variant thereof and a non-enzymatic targeting domain that recruits a target protein. In some embodiments, the targeting domain is fused to the N-terminus of the ARRDC1 protein or variant thereof. In some embodiments, the targeting domain is fused to the C-terminus of the ARRDC1 protein or variant thereof. In some embodiments, the ARRDC1 protein or variant thereof is fused to the targeting domain by a linker. In some embodiments, the ARRDC1 protein or variant thereof comprises at least two PPXY motifs. In some embodiments, the at least two PPXY motifs are different. In some embodiments, the non-enzymatic targeting domain comprises an interaction domain. In some embodiments, the interaction domain comprises a non-enzymatic protein-binding peptide. In some embodiments, the target protein comprises a transcription factor, a protein product of a tumor promoter or oncogene, a developmental regulator, a growth factor, a metastasis promoter, an anti-apoptotic protein, a membrane-associated protein, a transmembrane receptor, an enzyme, a nuclease, a recombinase, or a reprogramming factor. In some embodiments, the non-enzymatic targeting domain comprises an intrabody. In some embodiments, the non-enzymatic targeting domain comprises a single domain antibody (sdAb). In some embodiments, the sdAb is a camelid single domain. In some embodiments, the end of the non-enzymatic targeting domain is fused to at least one additional PPXY motif. In some embodiments, the end of the non-enzymatic targeting domain is fused to at least two additional PPXY motifs. In some embodiments, the at least two additional PPXY motifs are different PPXY motifs. In some embodiments, the non-enzymatic targeting domain is fused to an Fc region of an antibody. In some embodiments, the non-enzymatic targeting domain or the Fc region of an antibody is fused to an RNA binding protein. In some embodiments, the RNA binding protein is a tat protein.In some embodiments, the tat protein is an HIV tat protein or a bovine immunodeficiency virus (BIV) tat protein. In some embodiments, the targeting domain comprises a binding aptamer. In some embodiments, the targeting domain is fused to a ubiquitin ligase. In some embodiments, the linker is a cleavable linker. In some embodiments, the cleavable linker comprises a protease cleavage site. In some embodiments, the protease cleavage site comprises a furin cleavage site, a viral protease cleavage site, or other cleavage site recognized by a viral protease. In some embodiments, the viral protease cleavage site comprises an HIV-1 protease cleavage site or a tobacco etch virus (TEV) cleavage site. In some embodiments, the cleavable linker is a photocleavable linker comprising a photocleavable protein or a fragment thereof. In some embodiments, the photocleavable linker comprises the photocleavable protein PhoCl1 (Zhang et al., Nat. Methods 2017 Apr;14(4):391-394; doi: 10.1038 / nmeth.4222) or a fragment thereof. In some embodiments, the photocleavable linker comprises a protein or protein fragment derived from PhoCl1, such as PhoCl2 (Lu et al., Chem. Sci., 2021 May 31;12(28):9658-9672; doi: 10.1039 / d1sc01059j). In some embodiments, the ubiquitin ligase is a ubiquibody. In some embodiments, the ubiquibody is CHIP (carboxyl terminus of Hsc70 interacting protein) or a fragment thereof.
[0004] In some embodiments, the non-enzymatic targeting domain of ARRDC1 fusion protein comprises a ubiquitination specific antibody domain. In some embodiments, the ARRDC1 fusion protein comprises one or more FLAG tags. In some embodiments, one or more of these FLAG tags comprise the sequence DYKDDDK (SEQ ID NO: 90). The present invention is, but is not limited to, a composition comprising a FLAG tag, and indeed additional compositions comprise one or more affinity tags (e.g., GST, His, CBP, MBP, etc.) and epitope tags (e.g., Myc, HA, etc.).
[0005] Further provided herein is an ARRDC1-mediated microvesicle (ARMM) comprising (i) a lipid bilayer and (ii) an ARRDC1 fusion protein or variant thereof disclosed herein. In some embodiments, the ARMM further comprises a fusion RNA, the fusion RNA comprising (i) an RNA sequence that binds to an RNA-binding protein and (ii) an expression sequence that encodes a ubiquitin ligase. In some embodiments, the RNA sequence is a TAR sequence. In some embodiments, the ubiquitin ligase is Trim21.
[0006] Further provided herein are nucleic acid constructs encoding the ARRDC1 fusion proteins disclosed herein.
[0007] Further provided herein is a microvesicle-producing cell comprising a recombinant expression construct encoding the ARRDC1 fusion protein disclosed herein under the control of a heterologous promoter. In some embodiments, the microvesicle-producing cell further comprises a recombinant expression construct encoding a fusion RNA under the control of a heterologous promoter, the fusion RNA comprising (i) an RNA sequence that binds to an RNA-binding protein and (ii) an expression sequence that encodes a ubiquitin ligase. In some embodiments, the RNA sequence is a TAR sequence. In some embodiments, the ubiquitin ligase is Trim21.
[0008] Further provided herein is a method of degrading a target protein, comprising contacting a target cell with a microvesicle disclosed herein.
[0009] Further provided herein is a method of altering the expression of at least one gene, comprising contacting a target cell with a microvesicle disclosed herein. In some embodiments, the expression of at least one gene is decreased. In some embodiments, the expression of at least one gene is increased.
[0010] Further provided is a method for preparing arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (ARMM), comprising (a) culturing a host cell comprising a recombinant expression construct encoding an ARRDC1 fusion protein under the control of a heterologous promoter in a medium, and (b) recovering the ARMM from the host cell or the medium. In some embodiments, the host cell has a reduced expression level of ubiquitin ligase compared to a wild-type host cell. In some embodiments, the host cell lacks ubiquitin ligase. In some embodiments, the host cell has a reduced expression level of the target protein compared to a wild-type host cell. In some embodiments, the host cell lacks the target protein.
[0011] Incorporation by Reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
[0012] The following detailed description of the embodiments of the invention will be better understood when read in conjunction with the accompanying drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently illustrated. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings. [Brief description of the drawings]
[0013] [Figure 1] Figure 1A shows a non-limiting schematic diagram of the fusion protein used for targeted protein degradation. In particular, ARRDC1 protein, which contains two PPXY (SEQ ID NO: 2) motifs, is fused to a polypeptide targeting domain. Figure 1B shows ARRDC1-RNA binding protein fusion, which contains a binding aptamer as targeting domain. [Diagram 2] FIG. 2A is a schematic diagram showing the fusion protein used for targeted protein degradation. In detail, ARRDC1 protein containing two PPXY (SEQ ID NO: 2) motifs is fused to anti-mCherry single domain antibody (sdAb). Anti-mCherry sdAb specifically recruits and binds mCherry fluorescent protein. FIG. 2B provides an immunofluorescence image showing that 293T cells co-transfected with the fusion protein expression construct of FIG. 2A and the mCherry expression construct have reduced mCherry protein levels. FIG. 2C provides a Western blot showing that 293T cells co-transfected with the fusion protein expression construct of FIG. 2A and the mCherry expression construct have reduced mCherry protein levels in a dose-dependent manner. [Diagram 3] Figure 3 shows a non-limiting schematic diagram of the fusion protein used for targeted protein degradation. In particular, the ARRDC1 protein containing two PPXY (SEQ ID NO: 2) motifs is fused to a targeting domain whose N-terminus is associated with two additional PPXY (SEQ ID NO: 2) motifs. [Figure 4] Figure 4 shows a non-limiting schematic diagram of the fusion protein used for targeted protein degradation. In detail, the ARRDC1 protein containing two PPXY (SEQ ID NO: 2) motifs is fused to a targeting domain fused to the Fc (fragment crystallizable) region of an antibody. The C-terminus of the targeting domain is further associated with a tat protein. The tat protein can recruit a TAR-Trim21 fusion RNA. Trim21 can ubiquitinate and degrade Fc-bound proteins. [Diagram 5] Figure 5 shows a non-limiting schematic diagram of a fusion protein used for targeted protein degradation. In particular, the ARRDC1 protein containing two PPXY (SEQ ID NO: 2) motifs is fused to a targeting domain fused to a ubiquibody such as CHIP. [Figure 6] Figure 6 shows a non-limiting schematic diagram of the fusion protein used for targeted protein degradation. In particular, as described above, a protease cleavage site is present between the ARRDC1 protein and the target recruitment / degradation module. [Figure 7] Figure 7 shows a non-limiting schematic diagram of the fusion protein used for targeted protein degradation. In detail, the ARRDC1 protein containing two PPXY (SEQ ID NO: 2) motifs is fused to a targeting domain fused to the Fc (fragment crystallizable) region of an antibody, and a protease cleavage site is present between the ARRDC1 protein and the target recruitment / degradation module as described above. [Figure 8] Figure 8 shows the results of a Western blot stained with anti-GAPDH (gel / blot loading control), anti-ARRDC1, and anti-mCherry. Negative controls are provided in lanes 1 and 5 of the Western blot. As shown in Figure 8, mCherry levels in target cells were not affected by the negative control but were reduced by ARMM-delivered ARRDC1 / anti-mCherry sdAb fusion protein, especially VSV-G pseudotyped ARMM particles. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] The present disclosure generally relates to an ARRDC1-mediated microvesicle (ARMM) degradation system and its use. Several aspects are described below with respect to illustrative application examples. It should be understood that numerous specific details, relationships, and methods are described to provide a complete understanding of the features described herein. However, a person of ordinary skill in the relevant field will readily recognize that the features described herein can be implemented without one or more specific details, or by using other methods. The features described herein are not limited by the order of acts or events shown, since some acts may occur in different orders and / or simultaneously with other acts or events. Moreover, not all acts or events shown are required to implement the methodology in accordance with the features described herein.
[0015] The terms used herein are merely intended to describe specific cases and are not intended to be limiting. As used herein, the singular forms "a", "an" and "the" are intended to include the plural unless the context clearly indicates otherwise. When ranges are used herein for physical properties such as molecular weight, or chemical properties such as chemical formulas, all combinations and subcombinations of the ranges and specific embodiments therein are intended to be included. The term "about" when referring to a numerical value or numerical range means that the numerical value or numerical range referred to is an approximation within experimental variation (or within statistical experimental error), and thus the numerical value or numerical range may vary between 1% and 15% of the stated numerical value or numerical range. The term "comprising" (and related terms such as "comprise" or "comprises" or "having" or "including") is not intended to exclude that certain other embodiments, such as embodiments of any composition of matter, composition, method, or process described herein, may "consist of" or "consist essentially of" the recited features.
[0016] definition As used herein, "antibody" refers to immunoglobulins and immunoglobulin fragments, whether natural or partially or wholly synthetically produced, such as by recombinant means, including any fragment thereof that comprises at least a portion of the variable region of an immunoglobulin molecule that retains the binding specificity capability of a full-length immunoglobulin. Thus, an antibody includes any protein having a binding domain that is homologous or substantially homologous to an immunoglobulin antigen-binding domain (antibody combining site). Antibodies also include single domain antibodies (sdAbs). Such sdAbs may be isolated from members of the mammalian family Camelidae, including llamas, camels, and alpacas. Single domain antibodies may comprise a peptide, ligand, or small heavy chain variable domain (VH). Single domain antibodies may be composed of sdAbs, peptides, ligands, or small variable domains (VHH) from camelids. Antibodies may include sdAbs that recognize tissue-specific markers, such as those disclosed in U.S. Pat. No. 9,816,080. Such sdAbs for use in the constructs provided herein can be selected via phage display libraries using methods known in the art (see, e.g., Velazquez EJ, Cress JD, Humpherys TB, Mortimer TO, Bellini DM, Skidmore JR, et al. (2022) Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy. PLoS ONE17(3): e0264822. https: / / doi.org / 10.1371 / journal.pone.0264822). Antibodies that promote ubiquitination (e.g., ubiquitination-specific antibodies) (e.g., sdAbs) can be incorporated into the constructs provided herein. Antibodies include antibody fragments.As used herein, the term "antibody" therefore includes synthetic antibodies, recombinantly produced antibodies, multispecific antibodies (e.g., bispecific antibodies), human antibodies, non-human antibodies, humanized antibodies, chimeric antibodies, intrabodies, and antibody fragments, such as, but not limited to, Fab fragments, Fab' fragments, F(ab')2 fragments, Fv fragments, disulfide-linked Fv (dsFv), Fd fragments, Fd' fragments, single-chain Fv (scFv), single-chain Fab (scFab), diabodies, anti-idiotypic (anti-Id) antibodies, or antigen-binding fragments of any of the above. Antibodies provided herein include members of any immunoglobulin type (e.g., IgG, IgM, IgD, IgE, IgA, and IgY), any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass (e.g., IgG2a and IgG2b).
[0017] As used herein, an "antibody fragment" or "antigen-binding fragment" of an antibody refers to any portion of a full-length antibody that is less than full-length but contains at least a portion of the variable region of the antibody that binds to the antigen (e.g., one or more CDRs and / or one or more antibody binding sites), and thus retains the binding specificity and at least a portion of the specific binding ability of the full-length antibody. Thus, an antigen-binding fragment refers to an antibody fragment that contains an antigen-binding portion that binds to the same antigen as the antibody from which the antibody fragment is derived. Antibody fragments include antibody derivatives produced by enzymatic treatment of a full-length antibody, as well as derivatives that are synthetically, e.g., recombinantly, produced. Antibody fragments are included among antibodies. Examples of antibody fragments include, but are not limited to, single domain antibodies (sdAbs), Fab, Fab', F(ab')2, single chain Fv (scFv), Fv, dsFv, diabodies, Fd and Fd' fragments, and other fragments including modified fragments (see, for example, Methods in Molecular Biology, Vol 207: Recombinant Antibodies for Cancer Therapy Methods and Protocols (2003); Chapter 1; p 3-25, Kipriyanov). Fragments can include multiple chains linked together, for example, by disulfide bonds and / or by peptide linkers. Antibody fragments generally contain at least or about 50 amino acids, and typically contain at least or about 200 amino acids. Antigen-binding fragments include antibody fragments that, when inserted into an antibody framework (e.g., by replacing the corresponding region), result in an antibody that immunospecifically binds to the antigen (i.e., exhibits a Ka of at least, or at least about, 107-108 M-1).
[0018] As used herein, the term "aptamer" refers to a nucleic acid that binds to a specific target molecule, such as an RNA-binding protein. In some embodiments, nucleic acid (e.g., DNA or RNA) aptamers are engineered to bind to various molecular targets, such as proteins, small molecules, macromolecules, metabolites, carbohydrates, metals, nucleic acids, cells, tissues, and organisms, by repeated in vitro selection, or similarly, by SELEX (Systematic Evolution of Ligands by Exponential Enrichment) methodology. Methods for engineering aptamers that bind to various molecular targets, e.g., proteins, are known in the art and are described in U.S. Pat. Nos. 6,376,19 and 9,061,043; Shui B., et al., "RNA aptamers that functionally interact with green fluorescent protein and its derivatives." Nucleic Acids Res., Mar; 40(5): e39 (2012); Trujillo UH, et al., "DNA and RNA aptamers: from tools for basic research towards therapeutic applications." Comb Chem High Throughput Screen 9 (8): 619-32 (2006); Srisawat C., et al., "Streptavidin aptamers: Affinity tags for the study of RNAs and ribonucleoproteins." RNA, 7:632-641 (2001); and Tuerk and Gold, "Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase." Science. 1990, the entire contents of each of which are incorporated herein by reference.
[0019] As used herein, the term "ARMM" refers to a microvesicle containing ARRDC1 protein or a variant thereof. The molecular mechanism by which ARMM is produced is described in US Pat. No. 1,094,5954, which is incorporated herein by reference. In some embodiments, ARMM is excreted from a cell and comprises a molecule, e.g., a nucleic acid, a protein, or a small molecule, present in the cytoplasm of the cell. In some embodiments, ARMM is excreted from a transgenic cell that comprises a recombinant expression construct that includes a transgene, and ARMM comprises a gene product, e.g., a transcript or a protein, encoded by the expression construct. In some embodiments, ARMM is synthetically produced, for example, by contacting a lipid bilayer with ARRDC1 protein in a cell-free system in the presence of TSG101, HECT domain ligase, and VPS4a. In some embodiments, ARMM lacks late endosomal markers. Some ARMM as provided herein do not contain or are negative for one or more exosome biomarkers. Exosome biomarkers are known to those skilled in the art and include, but are not limited to, CD63, Lamp-1, Lamp-2, CD9, HSPA8, GAPDH, CD81, SDCBP, PDCD6IP, ENOi, ANXA2, ACTB, YWHAZ, HSP90AAi, ANXAS, EEFiAi, YWHAE, PPIA, MSN, CFL1, ALDOA, PGKi, EEF2, ANXA1, PKM2, HLA-DRA, and YWHAB. For example, some ARMMs provided herein lack CD63, some ARMMs lack LAMP1, some ARMMs lack CD9, some ARMMs lack CD81, some ARMMs lack CD63 and Lamp1, some ARMMs lack CD63, Lamp1, and CD9, some ARMMs lack CD63, Lamp-1, CD81, and CD9, etc. Certain ARMM provided herein can include exosome biomarkers.Thus, some ARMM can be negative for one or more exosome biomarkers, but positive for one or more different exosome biomarkers.For example, such ARMM may be negative for CD63 and Lamp-1, but may contain PGKi or GAPDH; or may be negative for CD63, Lamp-1, CD9, and CD81, but may be positive for HLA-DRA. In some embodiments, ARMM includes exosomal biomarkers, but at a lower level than that identified in exosomes. For example, some ARMM include one or more exosomal biomarkers at a level of less than about 1%, less than about 5%, less than about 10%, less than about 20%, less than about 30%, less than about 40%, or less than about 50% of the level of the biomarker identified in exosomes. By way of non-limiting example, in some embodiments, ARMM may be negative for CD63 and Lamp-1, include CD9 at a level of less than about 5% of the level of CD9 typically identified in exosomes, and may be positive for ACTB. In addition to those listed above, exosomal biomarkers are known to those skilled in the art, and the present invention is not limited in this regard.
[0020] As used herein, the term "associated with," when used in reference to two or more molecular entities, e.g., fusion proteins, molecules, nucleic acids, means that the entities are physically associated or connected to one another, either directly or through one or more additional moieties that function as linkers, to form a structure that is sufficiently stable such that the entities remain physically associated under the conditions in which the structure is used, e.g., physiological conditions. In some embodiments, the association is via a linker, e.g., a cleavable linker.
[0021] As used herein, the term "binding RNA" refers to a ribonucleic acid (RNA) that binds to an RNA-binding protein, such as any RNA-binding protein known in the art and / or provided herein. In some embodiments, the binding RNA is an RNA that specifically binds to an RNA-binding protein. A binding RNA that "specifically binds" to an RNA-binding protein binds to the RNA-binding protein with higher affinity, binding activity, more readily, and / or with longer duration than it binds to another protein, such as a protein that does not bind to RNA or a protein that binds weakly to the binding RNA. In some embodiments, the binding RNA is a natural RNA or a non-natural variant thereof that binds to a specific RNA-binding protein. For example, the binding RNA may be a TAR element, a Rev response element, MS2 RNA, or any variant thereof that specifically binds to an RNA-binding protein. In some embodiments, the binding RNA may be a transactivation response element (TAR element) or a variant thereof, which is an RNA stem-loop structure found at the 5' end of nascent HIV-1 transcripts and specifically binds to the transactivator of transcription (Tat) protein. In some embodiments, the binding RNA is a Rev response element (RRE) or a variant thereof, which specifically binds to the accessory protein Rev (e.g., Rev from HIV-1). In some embodiments, the binding RNA is MS2 RNA, which specifically binds to the MS2 phage coat protein.
[0022] As used herein, the term "biologically active agent" is used to refer to an agent other than the ARMM or ARRDC1 fusion protein according to the present invention, which is used in combination with or alternating with the ARMM or ARRDC1 fusion protein as an agent having a biological activity that helps achieve the intended or desired result of treatment, inhibition and / or prevention / prophylaxis for which the compound of the present invention is used. Biologically active agents as used herein may include agents having pharmacological activity similar to that for which the ARMM or ARRDC1 fusion protein is used or administered, including, for example, anticancer agents, antiviral agents, antibacterial agents, antifungal agents, etc.
[0023] "Derivatives" include polypeptides or fragments thereof that have conservative amino acid substitutions relative to a second polypeptide; or polypeptides or fragments thereof that have been modified by the covalent attachment of a second molecule, e.g., by the attachment of a heterologous polypeptide, or by glycosylation, acetylation, phosphorylation, etc. For example, peri-peptides that contain one or more analogs of an amino acid (e.g., unnatural amino acids, etc.), polypeptides with unsubstituted linkages, and other modifications known in the art, both natural and unnatural.
[0024] As used herein, the term "domain" refers to a folded protein structure that retains its tertiary structure independent of the rest of the protein. Generally, domains are responsible for distinct functional properties of a protein and can often be added, removed, or introduced into other proteins without impairing the function of the rest of the protein and / or the domain.
[0025] As used herein, "expression" of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA transcript from a DNA sequence (e.g., by transcription); (2) processing of the RNA transcript (e.g., by splicing, editing, 5' capping, and / or 3' end processing); (3) translation of the RNA transcript into a polypeptide or protein; and (4) post-translational modification of the polypeptide or protein.
[0026] As used herein, the term "fragment" refers to a fragment of a complete wild-type sequence that still retains the binding function of the wild-type protein from which it is derived (e.g., a fragment of a target protein still allows binding to a compound that mediates interaction with ubiquitin ligase). The fragment may suitably comprise at least 10 amino acids in length, for example, 25, 50, 75, 80, 90, 100, 110, 120, or 130 amino acids in length. The fragment may also comprise a C-terminal or N-terminal truncation.
[0027] As used herein, the term "fusion protein" generally refers to a protein that is translated from a fusion gene that is made by combining parts of two different genes / nucleic acid sequences.ARRDC1 or its variant and nonenzymatic targeting domain are preferably associated with each other by genetic fusion (i.e., fusion protein is generated by translation of nucleic acid in which the polynucleotide that codes for all or part of ARRDC1 is linked in frame with the polynucleotide that codes for all or part of nonenzymatic targeting domain) or chemical binding.
[0028] As used herein, the term "fusion RNA" generally refers to RNA transcribed from a fusion gene made by joining parts of two different genes / nucleic acid sequences. In the present disclosure, the RNA sequence that binds to the RNA-binding protein is associated with the expression sequence of ubitin ligase (e.g., Trim21 mRNA) by genetic fusion or chemical conjugation with each other.
[0029] As used herein, the term "interaction domain" refers to a peptide or protein adapted to specifically interact with a target region (or target) on another molecule distinct from itself.
[0030] As used herein, the term "intrabody" refers to a form of antibody that is not secreted from the cell in which it is produced, but rather targets one or more intracellular proteins. Intrabodies can be used to affect a number of cellular processes, including, but not limited to, intracellular trafficking, transcription, translation, metabolic processes, growth signaling, and cell division. Intrabodies are generally expressed intracellularly via delivery of an expression cassette that encodes the antibody, typically as an scFv, and contains various localization signals to target the antibody to the intracellular compartment of interest (see Lo et al. (2008) Handb Exp Pharmacol 181:343-373, incorporated herein in its entirety). Methods for stabilizing intrabodies are known in the art and include, but are not limited to, modifications of immunoglobulin VL domains that result in hyperstability (Cohen (1998) Oncogene 17(19):2445-2456), or expression of antibodies as fusion proteins with other stable intracellular proteins such as maltose binding protein (Shaki-Loewenstein (2005) J Immunol Methods 303(1-2):19-39).
[0031] As used herein, the term "linker" refers to a chemical moiety that connects two molecules or moieties, such as an ARRDC1 protein and a targeting domain, or a targeting domain and a Tat protein. Typically, a linker is placed between or sandwiched between two groups, molecules, or other moieties and is connected to each through a covalent bond, thereby connecting the two. In some embodiments, the linker comprises an amino acid or multiple amino acids (e.g., a peptide or protein). In some embodiments, the linker comprises a nucleotide (e.g., DNA or RNA) or multiple nucleotides (e.g., a nucleic acid). In some embodiments, the linker is an organic molecule, group, polymer, or other chemical moiety. In some embodiments, the linker is a cleavable linker, e.g., the linker comprises a bond that can be cleaved when exposed to, for example, ultraviolet light or a hydrolytic enzyme, such as a lysosomal protease. In some embodiments, the linker is any stretch of amino acids having at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50 amino acids, or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids). In other embodiments, the linker is a chemical bond (e.g., a covalent bond).
[0032] As used herein, the term "linker peptide" refers to a peptide used in association with at least one other peptide or protein, preferably in the form of a fusion protein.
[0033] As used herein, the term "microvesicle" refers to a droplet surrounded by a lipid bilayer. In some embodiments, the microvesicle has a diameter of about 10 nm to about 1000 nm. In some embodiments, the microvesicle has a diameter of at least about 10 nm, at least about 20 nm, at least about 30 nm, at least about 40 nm, at least about 50 nm, at least about 60 nm, at least about 70 nm, at least about 80 nm, at least about 90 nm, at least about 100 nm, at least about 125 nm, at least about 150 nm, at least about 175 nm, at least about 200 nm, at least about 250 nm, at least about 300 nm, at least about 400 nm, or at least about 500 nm. In some embodiments, the microvesicles have a diameter of less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 90 nm, less than about 80 nm, less than about 70 nm, less than about 60 nm, or less than about 50 nm. In some embodiments, the microvesicles have a diameter of about 50 to about 70 nm as measured by nanoscale flow analysis (e.g., using a Flow Nanoanalyzer from NanoFCM) or transmission electron microscopy (TEM). In some embodiments, the microvesicles have a diameter of about 70 to about 110 nm as measured by nanoparticle tracking analysis (NTA). In some embodiments, the microvesicles have a diameter of about 70 to about 90 nm as measured by tunable resistive pulse sensing (TRPS). In some embodiments, the microvesicles have a diameter of about 70 to about 90 nm as measured by tunable resistive pulse sensing (TRPS). The term "microvesicle" includes microvesicles that are excreted from cells as well as synthetically produced microvesicles. Microvesicles that are excreted from cells typically contain antigenic components of the cells from which they are derived.Microvesicles excreted from cells also typically comprise an asymmetric distribution of phospholipids, reflecting the phospholipid distribution of the cells from which they are derived. In some embodiments, the inner membrane of the microvesicles provided herein, such as the inner membrane of some ARMMs, comprises a majority of aminophospholipids, phosphatidylserine, and / or phosphatidylethanolamine within the lipid bilayer.
[0034] As used herein, the term "neoplasm" or "cancer" refers to the pathological process that results in the formation and growth of cancerous or malignant neoplasms, i.e., abnormal tissue that grows by cellular proliferation, often grows faster than normal, and continues to grow after the stimulus that initiated the new growth has ceased. Malignant neoplasms are partially or completely devoid of structural and functional association with normal tissues, often invade surrounding tissues, metastasize to multiple sites, tend to recur even after attempted resection, and may cause death to the patient unless properly treated. As used herein, the term neoplasm is used to describe all cancerous disease states and encompasses or encompasses the pathological processes associated with malignant hematogenous, ascites, and solid tumors. Exemplary cancers that may be treated by the compounds of the present invention, alone or in combination with at least one additional anti-cancer agent, include squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinoma, and renal cell carcinoma, cancer of the bladder, intestine, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemia; benign and malignant lymphomas, particularly Burkitt's lymphoma and non-Hodgkin's lymphoma; benign and malignant melanoma; myeloproliferative disorders; Ewing's sarcoma, angiosarcoma, Kaposi's sarcoma, lipomas, and sarcomas. Sarcomas, including liposarcoma, myosarcoma, peripheral neuroepithelioma, synovial sarcoma, glioma, astrocytoma, oligodendroglioma, ependymoma, glioblastoma, neuroblastoma, ganglioneuroma, ganglioglioma, medulloblastoma, pineal cell tumor, meningioma, meningeal sarcoma, neurofibroma, and Schwannoma; colorectal cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, gastric cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor, and teratocarcinoma. Additional cancers that may be treated using the compounds according to the invention include, for example, T-acute lymphoblastic leukemia (T-ALL), T-lymphoblastic lymphoma (T-LL), peripheral T-cell lymphoma, adult T-cell leukemia, pre-B ALL, pre-B lymphoma, large B-cell lymphoma, Burkitt's lymphoma, B-cell ALL, Philadelphia chromosome positive ALL, and Philadelphia chromosome positive CML.
[0035] As used herein, the term "non-enzymatic targeting domain" generally refers to a targeting domain that does not include an enzyme or an enzymatically active fragment thereof.
[0036] As used herein, the term "recruit" refers to the attraction of an entity, such as a protein or RNA molecule, to a targeting domain or an RNA binding domain. The entity may bind to the targeting domain or the RNA binding domain.
[0037] As used herein, the term "reprogramming factor" refers to a factor that can change the state of a cell from the differentiated state of a somatic cell to a pluripotent stem cell state, either alone or in combination with other factors.Non-limiting examples of reprogramming factors include proteins (e.g., transcription factors), peptides, nucleic acids, or small molecules.Known reprogramming factors that are useful for cell reprogramming include, but are not limited to, Oct4, Sox2, Klf4, and c-myc.Similarly, programming factors can be used to modulate cell differentiation, for example, to promote or induce cell differentiation into desired lineages.
[0038] As used herein, the term "RNA binding protein" refers to a polypeptide molecule that binds to a binding RNA, for example, any of the binding RNAs known in the art and / or provided herein. In some embodiments, the RNA binding protein is a protein that specifically binds to a binding RNA. An RNA binding protein that "specifically binds" to a binding RNA binds to the binding RNA with higher affinity, avidity, more readily, and / or with a longer duration than it binds to another RNA, for example, a control RNA (e.g., an RNA with a random nucleic acid sequence) or an RNA that binds weakly to the RNA binding protein. In some embodiments, the RNA binding protein is a natural protein that binds to a specific RNA, or a non-natural variant thereof. For example, in some embodiments, the RNA binding protein can be a transactivator of transcription (Tat) protein that specifically binds to a transactivation response element (TAR element). In some embodiments, the RNA binding protein is a virion expression regulator (Rev) protein (e.g., Rev from HIV-1) or a variant thereof that specifically binds to a Rev response element (RRE). In some embodiments, the RNA binding protein is a coat protein of MS2 bacteriophage that specifically binds to MS2 RNA. An RNA-binding protein useful in the present disclosure (e.g., a binding protein fused to ARRDC1) can be designed to specifically bind to a binding RNA (e.g., a binding RNA fused to an mRNA encoding a ubiquitin ligase such as Trim21) to facilitate ubiquitination of a target protein.
[0039] As used herein, the term "subject" refers to any organism to which a composition according to the invention can be administered, for example, for experimental, diagnostic, prophylactic, and / or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans) and / or plants.
[0040] As used herein, the term "target protein" generally refers to the protein that is targeted and recruited to the nonenzymatic targeting domain. For example, the target protein can be an antigen or a ligand. The target protein can be a transcription factor, a tumor promoter, or a protein product of an oncogene, a development regulator, a growth factor, a metastasis promoter, an anti-apoptotic protein, a membrane-associated protein, a transmembrane receptor, an enzyme, a nuclease, a recombinase, or a reprogramming factor. In some embodiments, the ARRDC1 fusion protein and ARMM disclosed herein are engineered to bring ubiquitin ligase into close proximity with the target, promote the ubiquitination of the target protein, and ultimately promote its target degradation by the proteosome pathway.
[0041] As used herein, the term "targeting domain" refers to an oligomer or polymer composed of nucleic acid or amino acid subunits capable of binding to a specific target, such as an antigen or ligand. A targeting domain may be, for example, any type of aptamer or protein that binds to a target protein.
[0042] As used herein, the term "therapeutically effective amount" means an amount of an agent (e.g., a nucleic acid, drug, therapeutic agent, diagnostic agent, prophylactic agent, etc.) delivered that is sufficient, when administered to a subject suffering from or susceptible to a disease, disorder, and / or condition, to treat, ameliorate symptoms, diagnose, prevent, and / or delay the onset of the disease, disorder, and / or condition.
[0043] As used herein, the term "transcription factor" refers to a DNA-binding protein that controls transcription from DNA to RNA, for example, by activating or repressing transcription. Some transcription factors control transcription alone, while others work in conjunction with other proteins. Some transcription factors can activate or repress transcription under certain conditions. In general, transcription factors bind to target sequences that are specific to a particular consensus sequence in the regulatory region of a target gene, or sequences that are very similar to it. Transcription factors can control the transcription of target genes alone or in complex with other molecules.
[0044] As used herein, the term "treat" refers to partially or completely alleviating, relieving, improving, relieving, delaying onset, inhibiting progression, reducing severity, and / or reducing onset of one or more symptoms or characteristics of a particular disease, disorder, and / or condition. For example, "treating" cancer may refer to inhibiting tumor survival, growth, and / or spread. Treatment may be performed on subjects who do not show signs of a disease, disorder, and / or condition and / or on subjects who show only early signs of a disease, disorder, and / or condition, with the aim of reducing the risk of developing pathologies associated with the disease, disorder, and / or condition.
[0045] As used herein, the term "ubiquibody" generally refers to a protein chimera that combines the activity of an E3 ubiquitin ligase with a designer binding protein to recruit target proteins to the UPP for degradation, such as the modular human E3 ubiquitin ligase CHIP (carboxyl terminal of Hsc70 interacting protein) whose native substrate binding domain has been replaced by a single chain Fv (scFv) intrabody or a fibronectin type III domain monobody that targets the respective antigen with high specificity and affinity. Additional information regarding ubiquibodies can be found in Alyse Portnoff, Erin Stephens, Jeffrey Varner, et al., "Ubiquibodies, Synthetic E3 Ubiquitin Ligases Endowed with Unnatural Substrate Specificity for Targeted Protein Silencing," J Bio Chem, Vol 289, No. 11, pp. 7844-7855, March 14, 2014, which is incorporated by reference in its entirety.
[0046] As used herein, the term "ubiquitin ligase", also known as E3 ligase, refers to a family of proteins that facilitate the transfer of ubiquitin, alone or in complexes, to specific substrate proteins, thereby targeting the substrate proteins for degradation. E3 ubiquitin ligases are classified into five classes, with two major classes (HECT (homologous to E6-AP carboxyl terminus) catalytic domain E3 ligases and zinc-binding RING (new genes of great interest) finger adaptor domain E3 ligases) and three minor classes (U Box, PHD, and HUL-1 E3 ligases). For example, neural precursor cell expressed developmentally downregulated protein 4 (NEDD4) is a HECT domain E3 ligase that plays multiple roles in cell signaling. Ubiquitination by NEDD4 involves initial binding of a ubiquitin-binding E2 to the HECT domain of NEDD4, followed by a thiol ester exchange for the transfer of a ubiquitin moiety from the E2 to the catalytic cysteine of NEDD4. The bound ubiquitin moiety is then transferred to a target protein or to another ubiquitin molecule, promoting a polyubiquitin chain. In either case, ubiquitin is transferred from the E3 catalytic cysteine to a lysine side chain ε-amino group. Polyubiquitination can mark proteins for degradation by the proteasome.
[0047] As used herein, the term "ubiquitination" refers to the attachment of the protein ubiquitin to lysine residues of other molecules. Ubiquitination of a molecule, such as a peptide or protein, can act as a signal for the rapid cellular degradation of the molecule and targeting to the proteasome complex.
[0048] As used herein, the term "variable" refers to the fact that certain segments of the variable domains vary widely in sequence among antibodies. The variable domains mediate antigen binding and define the specificity of a particular antibody for its particular antigen. However, variability is not evenly distributed across the amino acid span of the variable domain. Instead, the variable domain region consists of relatively invariant stretches called framework regions (FRs) of 15-30 amino acids separated by short regions of extreme variability called "hypervariable regions", each of which is 9-12 amino acids long. Naturally occurring heavy and light chain variable domains each consist of four FRs, mostly in a β-sheet structure, connected by three hypervariable regions, which form loops that connect the β-sheet structure and, in some cases, form part of the β-sheet structure. The hypervariable regions of each chain are held in close proximity by the FRs and, together with the hypervariable regions of the other chain, contribute to the formation of the antigen-binding site of the antibody. See Kabat et al. (1991). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular cytotoxicity (ADCC).
[0049] As used herein, the term "variant" includes variants that have an amino acid sequence or nucleotide sequence similar to the original (e.g., wild-type) sequence, but have one or more amino acid or nucleotide changes, resulting in variants that still retain the function of the original protein from which they are derived. For example, variants of target proteins described herein include variants that still facilitate sufficient binding to compounds that allow ubiquitination of the polypeptide sequence via ubiquitin ligase.
[0050] Ubiquitin-Protease Pathway (UPP) Ubiquitin is a small (~8.5 kDa) protein found in most tissues of eukaryotes. The addition of ubiquitin to a substrate protein is called ubiquitination or ubiquitylation. Ubiquitination can affect proteins in a variety of ways, including signaling for degradation via the proteasome. Ubiquitin is covalently attached to substrate lysines by the activity of an E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase) enzyme cascade. E3 ubiquitin RING ligase is a protein that recruits ubiquitin-loaded E2 ubiquitin-conjugating enzymes, so that the E3 ubiquitin RING ligase interacts with both the target protein and the E2 enzyme. The protein substrate is then ubiquitinated and subsequently degraded by the proteasome.
[0051] E3 ubiquitin ligase, such as cereblon, can ubiquitinate target proteins when the target protein is placed in the vicinity of E3 ubiquitin ligase. The ARRDC1 fusion protein and ARMM disclosed herein are engineered to bring ubiquitin ligase into the vicinity of target proteins, promote ubiquitination of target proteins, and ultimately promote their target degradation by the proteosome pathway. Thus, in some embodiments, the present disclosure provides proximity-induced ubiquitination and subsequent degradation. The present disclosure provides multiple approaches to achieving the desired juxtaposition of a target protein and a ubiquitin ligase, including embodiments in which a targeting domain is covalently (e.g., fusion with ARRDC1) or non-covalently (e.g., an aptamer bound to ARRDC1 via an RNA binding protein fused to ARRDC1) associated with ARRDC1 to bring the target protein into proximity with the ubiquitin ligase recruited by ARRDC1, as well as embodiments that supply ubiquitin ligase activity, such as by fusing a ubiquibody (e.g., a construct comprising a targeting domain and a ubiquitin ligase) to ARRDC1, or by fusing a targeting domain to the Fc region with an RNA binding protein that binds to a target RNA encoding a ubiquitin ligase (e.g., TRIM21).
[0052] Ubiquitin ligase As mentioned above, E3 ubiquitin ligases can recruit ubiquitin-loaded E2 ubiquitin-conjugating enzymes, recognize protein substrates, and facilitate the transfer of ubiquitin from E2 to target proteins. E3 ubiquitin ligases largely determine substrate specificity. There are hundreds of ubiquitin protein ligases in mammals. These can be classified into two main groups: RING E3s, which mediate the direct transfer of ubiquitin to substrates, and HECT E3s, including NEDD4 family members, which are involved in the transfer of activated ubiquitin from E2 to substrates by forming an intermediate complex with the C-terminus of E3s. See N. Boase and S Kumar, "NEDD4: The founding member of a family of ubiquitin-protein ligases," Gene, 2015 Feb 25; 557(2): 113-122. Exemplary ubiquitin ligases include, but are not limited to, HECW2 (E3 ubiquitin protein ligase 2 containing HECT, C2 and WW domains), HECW1 (E3 ubiquitin protein ligase 1 containing HECT, C2 and WW domains), WWPL (E3 ubiquitin protein ligase 1 containing WW domains), WWP2 (WW domain-containing protein 2), NEDD4-1 (neural progenitor cell expressed developmentally downregulated 4-1), NEDD4-2 (neural progenitor cell expressed developmentally downregulated 4-2), NEDD4-3 (neural progenitor cell expressed developmentally downregulated 4-3), NEDD4-4 (neural progenitor cell expressed developmentally downregulated 4-4), NEDD4-5 (neural progenitor cell expressed developmentally downregulated 4-5), NEDD4-6 (neural progenitor cell expressed developmentally downregulated 4-6), NEDD4-7 (neural progenitor cell expressed developmentally downregulated 4-7), NEDD4-8 (neural progenitor cell expressed developmentally downregulated 4-8), NEDD4-9 (neural progenitor cell expressed developmentally downregulated 4-9), NEDD4-10 (neural progenitor cell expressed developmentally downregulated 4-9), NEDD4-11 (neural progenitor cell expressed developmentally downregulated 4-9), NEDD4-12 (neural progenitor cell expressed developmentally downregulated 4-9), NEDD4-13 (neural progenitor cell expressed developmentally downregulated 4-9), NEDD4-14 (neural progenitor cell expressed developmentally downregulated 4-9), NEDD4-15 (neural progenitor cell expressed developmentally downregulated 4-9), NEDD4-16 (neural progenitor cell expressed developmentally downregulated 4-9), NEDD4-17 ( downregulated 4-2), NEDD4L (NEDD4-like E3 ubiquitin protein ligase), SMURFL (Smad ubiquitination regulator-L), SMURF2 (Smad ubiquitin regulator 2), SMURF1 (Smad ubiquitin regulator 1), ITCH, NEDL1 (HECT-type ubiquitin protein isopeptide ligase 1), NEDL2 (HECT-type ubiquitin protein isopeptide ligase 2), and TRIM21 (tri-element motif-containing protein 21).
[0053] Ubiquitous Body In some embodiments, the ARRDC1 protein or variant thereof is fused to a ubiquitin ligase. In some embodiments, the ubiquitin ligase is a ubiquibody. A ubiquibody is an engineered protein chimera that combines the ubiquitination activity of an E3 ubiquitin ligase with the binding affinity and substrate specificity of a designer binding protein (DBP). See Morgan Baltz, Erin Stephens, and Matthew DeLisa, "Design and Functional Characterization of Synthetic E3 Ubiquitin Ligases for Targeted Protein Depletion: selective protein knockout using engineered ubiquibodies," Curr Protoc Chem Biol., 2018 March; 10(1): 72-90. Ubiquibodies facilitate the redirection and proteolysis of specific substrate targets that may not otherwise bind to the proteasome. A ubiquibody may comprise a degradation domain (e.g., a ubiquitin ligase catalytic domain) and a targeting domain capable of specifically directing the degradation domain to a substrate, the targeting domain being heterologous to the degradation domain. A linker may connect the degradation domain to the targeting domain. In some embodiments, the degradation domain comprises a eukaryotic U-box motif. Further information regarding ubiquibodies can be found in WO 2012 / 135284, which is incorporated herein by reference in its entirety.
[0054] ARRDC1 protein ARRDC1 is a protein that contains PSAP (SEQ ID NO: 1) and PPXY (SEQ ID NO: 2) motifs at its C-terminus, also referred to herein as PSAP and PPXY domains, respectively. Exemplary non-limiting ARRDC1 protein sequences are provided herein, and additional suitable ARRDC1 protein sequences, isoforms, and fragments according to embodiments of the present invention are known in the art. Those skilled in the art will understand that the present invention is not limited in this respect. Additional information regarding ARRDC1 is provided in US Pat. No. 10,945,954 and US Pat. No. 10,260,055, which are incorporated herein by reference. Exemplary ARRDC1 sequences include (PSAP and PPXY motifs are marked): >gi|22748653|ref|NP_689498.1|Arrestin domain-containing protein 1 [Human (Homo sapiens)]
[0055] [ka]
[0056] >gi|244798004|ref|NP_001155957.1|Arrestin domain-containing protein 1 isoform a [Mus musculus]
[0057] [ka]
[0058] >gi|244798112|ref|NP_848495.2|Arrestin domain-containing protein 1 isoform b [Mus musculus]
[0059] [ka]
[0060] The ARRDC1 PPXY motif has been shown to recruit E3 ubiquitin ligases from the NEDD4 family, including, but not limited to, HECW2, HECW1, NEDD4, NEDD4L, SMURF2, SMURF1, WWP1, WWP2, and ITCH. Without being limited to any particular theory, the proximity of a target protein to an ARRDC1-bound ubiquitin ligase can ubiquitinate the target protein and drive its degradation by the proteasome.
[0061] In some embodiments, the ARRDC1 protein or variant thereof is an ARRDC1 protein fragment. In some embodiments, the ARRDC1 protein fragment is a C-terminal ARRDC1 protein fragment. In some embodiments, the ARRDC1 protein fragment comprises a PSAP motif and at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290, or at least 300 consecutive amino acids of the ARRCD1 sequence. Additional information can be found in U.S. Pat. No. 1,0945,954, which is incorporated herein by reference in its entirety.
[0062] In some embodiments, the ARRDC1 protein or variant thereof comprises at least two PPXY motifs. In some embodiments, the ARRDC1 protein or variant thereof comprises at least three PPXY motifs. In some embodiments, the ARRDC1 protein or variant thereof comprises at least four PPXY motifs. In some embodiments, the ARRDC1 protein or variant thereof comprises at least five PPXY motifs. In some embodiments, the ARRDC1 protein or variant thereof comprises at least six PPXY motifs. In some embodiments, the ARRDC1 protein or variant thereof comprises at least two but fewer than ten PPXY motifs. In some embodiments, the ARRDC1 protein or variant thereof comprises at least two but fewer than six PPXY motifs. In some embodiments, the ARRDC1 protein or variant thereof comprises at least two but fewer than four PPXY motifs. In some embodiments, the ARRDC1 protein or variant thereof comprises two, three, four, five, or six PPXY motifs. In some embodiments, the PPXY motifs are the same. In some embodiments, at least some PPXY motifs are different. In some embodiments, all PPXY motifs are distinct from each other, i.e., no PPXY motif is the same as any other PPXY motif in the ARRDC1 protein or variant thereof. In some embodiments, the ARRDC1 protein or variant thereof comprises a PSAP motif.
[0063] ARRDC1 fusion protein Provided herein is an ARRDC1 fusion protein comprising an ARRDC1 protein or its variant and a non-enzymatic targeting domain that recruits a target protein. In some embodiments, the targeting domain is fused to the N-terminus of the ARRDC1 protein or its variant. In some embodiments, the targeting domain is fused to the C-terminus of the ARRDC1 protein or its variant. In some embodiments, the ARRDC1 protein or its variant is covalently linked to the targeting domain. In some embodiments, the ARRDC1 protein or its variant is non-covalently linked to the targeting domain. In some embodiments, the ARRDC1 protein or its variant is fused to the targeting domain by a linker.
[0064] In some embodiments, the non-enzymatic targeting domain comprises an interaction domain. In some embodiments, the interaction domain comprises a non-enzymatic protein-binding peptide. In some embodiments, the non-enzymatic protein-binding peptide comprises an antibody, an antibody derivative, or an antibody fragment. In some embodiments, the non-enzymatic protein-binding peptide comprises an intrabody. In some embodiments, the intrabody comprises a single chain variable region, a nanobody, or a single domain antibody. In some embodiments, the single domain antibody is a camelid single domain. In some embodiments, the non-enzymatic protein-binding peptide comprises a ligand or a ligand fragment. In some embodiments, the non-enzymatic protein-binding peptide comprises an antigen or an antigen fragment. In some embodiments, the non-enzymatic targeting domain comprises an aptamer. In some embodiments, the non-enzymatic targeting domain comprises an alternative scaffold protein, for example, an engineered protein based on an ankyrin repeat motif (e.g., DARPin), an engineered protein based on the Z domain of protein A (e.g., affibody), an engineered protein based on a fibronectin type III domain protein (e.g., adnectin, trinectin, monobody, or centilin), an engineered protein based on an SH3 domain, such as the SH3 domain of the proto-oncogene fyn (e.g., fynomer), an engineered protein based on a lipocalin (e.g., anticalin). In some embodiments, the end of the non-enzymatic targeting domain is fused to at least one additional PPXY motif. In some embodiments, the end of the non-enzymatic targeting domain is fused to at least two additional PPXY motifs. In some embodiments, the end of the non-enzymatic targeting domain is fused to at least three additional PPXY motifs. In some embodiments, the end of the non-enzymatic targeting domain is fused to at least four additional PPXY motifs. In some embodiments, the terminus of the non-enzymatic targeting domain is fused to at least one but fewer than 10 additional PPXY motifs. In some embodiments, the terminus of the non-enzymatic targeting domain is fused to at least one but fewer than 8 additional PPXY motifs.In some embodiments, the end of the non-enzymatic targeting domain is fused to at least one but less than six additional PPXY motifs. In some embodiments, the end of the non-enzymatic targeting domain is fused to at least two but less than six additional PPXY motifs. In some embodiments, the end of the non-enzymatic targeting domain is fused to at least two but less than four additional PPXY motifs. In some embodiments, the end of the non-enzymatic targeting domain is fused to one additional PPXY motif. In some embodiments, the end of the non-enzymatic targeting domain is fused to two additional PPXY motifs. In some embodiments, the end of the non-enzymatic targeting domain is fused to three additional PPXY motifs. In some embodiments, the end of the non-enzymatic targeting domain is fused to four additional PPXY motifs. In some embodiments, the additional PPXY motifs are identical. In some embodiments, at least some of the additional PPXY motifs are different. In some embodiments, all additional PPXY motifs are different, i.e., additional PPXY motifs are not identical to another additional PPXY motif fused to nonenzymatic targeting domain.In some embodiments, the end of nonenzymatic targeting domain is N-terminus.In some embodiments, the end of nonenzymatic targeting domain is C-terminus.
[0065] In some embodiments, the target protein is an enzyme, a transcription factor, a tumor promoter, or a protein product of an oncogene, a developmental regulator, a growth factor, a metastasis promoter, an anti-apoptotic protein, a membrane-associated protein, a transmembrane receptor, an enzyme, a nuclease, a recombinase, a reprogramming factor, or a membrane-associated protein.
[0066] RNA-binding proteins In some embodiments, the non-enzymatic targeting domain is fused to an Fc region of an antibody. In some embodiments, the non-enzymatic targeting domain or the Fc region of an antibody is fused to an RNA binding protein.
[0067] In some embodiments, the RNA binding protein is a naturally occurring protein, or a non-naturally occurring variant thereof, or a non-naturally occurring protein that binds to RNA, for example, RNA with a particular sequence or structure.
[0068] In certain embodiments, the RNA binding protein is a transactivator of transcription (Tat) protein that specifically binds to a transactivation response element (TAR element). An exemplary Tat protein comprises the amino acid sequence set forth in SEQ ID NO:6 (Table 1). Exemplary amino acid sequences of Tat proteins, as well as Tat protein fragments that bind to TAR elements, are provided in Table 1. In some embodiments, the RNA binding protein is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs:6-25 and binds to a TAR element. In some embodiments, the RNA binding protein has at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 105, at least 110, at least 115, at least 120, at least 125, or at least 130 identical contiguous amino acids of any one of SEQ ID NOs:6-25 and binds to a TAR element. In some embodiments, the RNA binding protein has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more mutations compared to any one of the amino acid sequences set forth in SEQ ID NOs: 6-25, and binds to a TAR element. In some embodiments, the RNA binding protein comprises any one of the amino acid sequences set forth in SEQ ID NOs: 6-25. In some embodiments, the Tat protein comprises any one of the amino acid sequences set forth in SEQ ID NOs: 6-25. The RNA binding protein may also be a variant of the Tat protein capable of associating with a TAR element.Tat protein and variants of Tat protein that bind to TAR element are known in the art and have been described, for example, in Kamine et al., "Mapping of HIV-1 Tat Protein Sequences Required for Binding to Tar RNA", Virology 182, 570-577 (1991); and Patel, "Adaptive recognition in RNA complexes with peptides and protein modules" Curr Opin Struct Biol. 1999 Feb;9(1):74-87, the entire contents of each of which are incorporated herein by reference. In some embodiments, the Tat protein is HIV-1 Tat protein, or a variant thereof. In some embodiments, the Tat protein is bovine immunodeficiency virus (BIV) Tat protein, or a variant thereof.
[0069] The Tat protein consists of several domains, one of which is a short lysine- and arginine-rich region that is important for nuclear localization. The 9 amino acid basic region of HIV-1 Tat is found at positions 49-57 of SEQ ID NO:6 and is capable of binding to the TAR element. In some embodiments, the Tat sequence comprises the 9 amino acid basic region of Tat (SEQ ID NO:14). In some embodiments, the RNA binding protein comprises any one of the amino acid sequences set forth in SEQ ID NOs:6-8, 10, 11, or 14-25. In some embodiments, the Tat protein is a fusion protein.
[0070] [Table 1]
[0071] In some embodiments, the RNA binding protein is a virion expression regulator (Rev) protein (e.g., Rev from HIV-1) or a variant thereof that binds to a Rev response element (RRE). Rev proteins are known in the art and known to those of skill in the art. For example, the Rev protein is described in Fernandes et al., "The HIV-1 Rev response element: An RNA scaffold that directs the cooperative assembly of a homo-oligomeric ribonucleoprotein complex" RNA Biology 9:1, 6-11; January 2012; Cochrane et al., "The human immunodeficiency virus Rev protein is a nuclear phosphoprotein" Virology 171 (1):264-266, 1989; Grate et al., "Role REVersal: understanding how RRE RNA binds its peptide ligand" Structure. 1997 Jan 15; 5(1):7-11; and Patel, "Adaptive recognition in RNA complexes with peptides and protein modules" Curr Opin Struct Biol. 1999 Feb; 9(1):74-87, the entire contents of each of which are incorporated herein by reference in their entireties. Exemplary Rev proteins include the amino acid sequences set forth in SEQ ID NOs:28-30 (Table 2). In some embodiments, the RNA binding protein is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs:28-30 and binds to a Rev response element.In some embodiments, the RNA binding protein has at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 105, at least 110, or at least 115 identical contiguous amino acids of any one of SEQ ID NOs:28-30 and binds to a Rev response element. In some embodiments, the RNA binding protein has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more mutations compared to any one of the amino acid sequences set forth in SEQ ID NOs: 28-30, and binds to a Rev response element. In some embodiments, the RNA binding protein comprises any one of the amino acid sequences set forth in SEQ ID NOs: 28-30. In some embodiments, the RNA binding protein comprises any one of the variants of the amino acid sequences set forth in SEQ ID NOs: 28-30 that are capable of binding to an RRE. Such variants will be apparent to those of skill in the art based on this disclosure and knowledge in the art, and can be tested (eg, for binding to RRE) using routine methods known in the art.
[0072] [Table 2]
[0073] In some embodiments, the RNA binding protein is a coat protein of MS2 bacteriophage that specifically binds to MS2 RNA. MS2 phage coat proteins that specifically bind to MS2 RNA are known in the art. An exemplary MS2 phage coat protein comprises the amino acid sequence shown in SEQ ID NO: 34 (Table 3). In some embodiments, the RNA binding protein is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 34 and binds to MS2 RNA. In some embodiments, the RNA binding protein has at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 105, at least 110, or at least 115 identical contiguous amino acids of SEQ ID NO:34 and binds to MS2 RNA. In some embodiments, the RNA binding protein has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more mutations compared to SEQ ID NO: 34 and binds to MS2 RNA. In some embodiments, the RNA binding protein comprises the amino acid sequence shown in SEQ ID NO: 34. In some embodiments, the RNA binding protein comprises a fragment or variant of SEQ ID NO: 34 that is capable of binding to MS2 RNA. Methods for testing whether a variant or fragment of MS2 phage coat protein binds to MS2 RNA (e.g., SEQ ID NO: 34) can be performed using routine experimentation and are obvious to those skilled in the art.
[0074] [Table 3]
[0075] In some embodiments, the RNA binding protein is a P22 N protein (e.g., P22 N from bacteriophage) or a variant thereof that binds to P22boxB RNA. P22 N proteins are known in the art and are obvious to those skilled in the art. An exemplary P22 N protein that specifically binds to P22boxB RNA comprises the amino acid sequence NAKTRRHERRRKLAIERDTI (SEQ ID NO: 35).
[0076] In some embodiments, the RNA binding protein is a λ N protein (e.g., λ N from bacteriophage) or a variant thereof that binds to λ boxB RNA. λ N proteins are known in the art and are obvious to those skilled in the art. An exemplary λ N protein that specifically binds to X boxB comprises the amino acid sequence GSMDAQTRRRERRAEKQAQWKAAN (SEQ ID NO: 36).
[0077] In some embodiments, the RNA binding protein is a φ21 N protein (e.g., φ21 N from bacteriophage) or a variant thereof that binds to φ21boxB RNA. φ21 N proteins are known in the art and will be apparent to those skilled in the art. An exemplary φ21 N protein that specifically binds to φ21 boxB RNA comprises the amino acid sequence GTAKSRYKARRAELIAERR (SEQ ID NO: 37). The N-peptide binds as an a-helix and interacts primarily with the major groove side of the 5' half of the boxB RNA stem loop. The binding surface is defined by the surface complementarity of polar and non-polar interactions. The N-peptide complexed with the exposed surface of the φ21 boxB loop resembles the GNRA tetraloop-like fold of related λ and P22 bacteriophage N-peptide-boxB RNA complexes.
[0078] In some embodiments, the RNA binding protein is an HIV-1 nucleocapsid (e.g., a nucleocapsid from HIV-1) or a variant thereof that binds to SL3 yr RNA. HIV-1 nucleocapsid proteins are known in the art and will be apparent to those skilled in the art. An exemplary HIV-1 nucleocapsid that specifically binds to SL3 xv RNA comprises the amino acid sequence MQKGNFRNQRKTVKCFNCGKEGHIAKNCRAPRKKGCWKCGKEGHQMKDCTERQAN (SEQ ID NO: 38).
[0079] Additional information regarding RNA binding proteins can be found in WO 2018 / 67546, which is incorporated by reference in its entirety.
[0080] binding RNA Some aspects of the present disclosure relate to RNA molecules that bind to proteins. In some embodiments, the binding RNA is a natural RNA or a non-natural variant thereof that binds to a protein having a specific amino acid sequence or structure, or a non-natural RNA.
[0081] In certain embodiments, the binding RNA is a transactivation response element (TAR element), which is an RNA stem-loop structure found at the 5' end of the emerging human immunodeficiency virus-1 (HIV-1) transcript, and specifically binds to the transactivator of transcription (Tat) protein. In some embodiments, the TAR element is a bovine immunodeficiency virus (BIV) TAR. An exemplary TAR element comprises the nucleic acid sequence shown in SEQ ID NO: 25. Further exemplary TAR sequences can be found in Table 1. However, these sequences are not meant to be limiting, and additional TAR element sequences that bind to Tat protein or variants thereof are also within the scope of the present disclosure. The binding RNA can also be a variant of a TAR element that can associate with an RNA-binding protein, the transactivator of transcription (Tat protein), which is a regulatory protein involved in the transcription of the viral genome. A variant of a TAR element that can associate with Tat protein will be obvious to one of skill in the art based on this disclosure and knowledge in the art, and is within the scope of the present disclosure. Furthermore, the association of a TAR variant with a Tat protein or a Tat protein variant can be tested using conventional methods. TAR elements and variants of TAR elements that bind to Tat protein are known in the art. In some embodiments, the binding RNA comprises a nucleic acid sequence as set forth in SEQ ID NOs: 39-44. In some embodiments, the binding RNA comprises any variant of the nucleic acid sequence as set forth in SEQ ID NOs: 39-44 that can bind to Tat protein or its variants.
[0082] [Table 4]
[0083] In some embodiments, the binding RNA is a Rev response element (RRE) or a variant thereof that binds to a Rev protein (e.g., Rev from HIV-1). Rev response elements are known in the art and would be obvious to one of skill in the art for use in the present invention. Exemplary RRE nucleic acid sequences that bind to Rev include, but are not limited to, the nucleic acid sequences shown in SEQ ID NOs: 26 and 27 (Table 2).
[0084] In some embodiments, the binding RNA is an MS2 RNA that specifically binds to MS2 phage coat protein. Typically, the coat protein of the RNA bacteriophage MS2 binds to a specific stem-loop structure in the viral RNA (e.g., MS2 RNA) to achieve genome encapsidation and translational repression of replicase synthesis. RNAs that specifically bind to MS2 phage coat protein are known in the art and will be obvious to those of skill in the art. In some embodiments, an exemplary MS2 RNA that specifically binds to MS2 phage coat protein comprises a nucleic acid sequence set forth in any one of SEQ ID NOs: 31-33 (Table 3). In some embodiments, the binding RNA comprises a nucleic acid sequence set forth in any one of SEQ ID NOs: 31, 32, and 33.
[0085] In some embodiments, the binding RNA is an RNA that specifically binds to P22 N protein (e.g., P22 N from bacteriophage) or its variants. P22 N protein is known in the art and is obvious to those skilled in the art. An exemplary P22 boxB RNA that specifically binds to P22 N protein comprises the nucleic acid sequence shown in gcgcugacaaagcgc (SEQ ID NO: 45).
[0086] In some embodiments, the binding RNA is an RNA that specifically binds to λ N protein (e.g., λ N from bacteriophage) or a variant thereof. λ N protein is known in the art and will be apparent to those skilled in the art. An exemplary λ boxB RNA that specifically binds to λ N protein comprises the nucleic acid sequence shown in gggcccugaagaagggccc (SEQ ID NO: 46).
[0087] In some embodiments, the binding RNA is an RNA that specifically binds to φ21 N protein (e.g., φ21 N from bacteriophage) or a variant thereof. φ21 N protein is known in the art and is obvious to those skilled in the art. An exemplary φ21 boxB RNA that specifically binds to φ21 N protein comprises the nucleic acid sequence shown in ucucaaccuaaccguugaga (SEQ ID NO: 47).
[0088] In some embodiments, the binding RNA is an RNA that specifically binds to HIV-1 nucleocapsid protein (e.g., nucleocapsid from HIV-1) or a variant thereof. HIV-1 nucleocapsid protein is known in the art and is obvious to those skilled in the art. An exemplary RNA that specifically binds to HIV-1 nucleocapsid comprises the nucleic acid sequence shown in ggacuagcggaggcuagucc (SEQ ID NO: 48).
[0089] It should be understood that the binding RNA of the present disclosure need not be limited to natural RNA or its non-natural variants with recognized protein binding partners. In some embodiments, the binding RNA can also be synthetically generated RNA, such as RNA designed to specifically bind to a protein (e.g., an RNA-binding protein). In some embodiments, the binding RNA is designed to specifically bind to any protein of interest. In some embodiments, the binding RNA is an RNA generated by Systematic Evolution of Ligands by Exponential Enrichment (SELEX). The SELEX methodology is readily apparent to those of skill in the art and is described, for example, in U.S. Pat. Nos. 5,270,163; 5,817,785; 5,595,887; 5,496,938; 5,475,096; 5,861,254; 5,958,691; 5,962,219; 6,013,443; 6,030,776; 6,083,696; 6,110,900; 6,127,119; and 6,147,204; U.S. Patent Application Nos. 20030175703 and 20030083294; Potti et al. al., Expert Opin. Biol. Ther. 4:1641-1647 (2004), and Nimjee et al., Annu. Rev. Med. 56:555-83 (2005). SELEX technology has been used to evolve aptamers with extremely high binding affinity to various target proteins. For example, see Trujillo UH, et al., "DNA and RNA aptamers: from tools for basic research towards therapeutic applications". Comb Chem High Throughput Screen 9 (8): 619-32 (2006) for its disclosure of using SELEX to design aptamers that bind to vascular endothelial growth factor (VEGF).In some embodiments, the binding RNA is an aptamer that specifically binds to a target protein.
[0090] Additional information regarding binding RNA can be found in WO 2018 / 67546, which is incorporated by reference in its entirety.
[0091] Linker In some embodiments, the ARRDC1 protein or its variant is fused to the targeting domain via a linker. In some embodiments, the linker is a linker peptide. In some embodiments, the linker is cleavable.
[0092] In some embodiments, the linker peptide consists of about 100 amino acids. In some embodiments, the linker peptide consists of about 90 amino acids. In some embodiments, the linker peptide consists of about 80 amino acids. In some embodiments, the linker peptide consists of about 70 amino acids. In some embodiments, the linker peptide consists of about 60 amino acids. In some embodiments, the linker peptide consists of about 50 amino acids. In some embodiments, the linker peptide consists of about 40 amino acids. In some embodiments, the linker peptide consists of about 30 amino acids. In some embodiments, the linker peptide consists of about 20 amino acids. In some embodiments, the linker peptide consists of about 18 amino acids. In some embodiments, the linker peptide consists of about 15 amino acids. In some embodiments, the linker peptide consists of about 12 amino acids. In some embodiments, the linker peptide consists of about 11 amino acids. In some embodiments, the linker peptide consists of about 10 amino acids. In some embodiments, the linker peptide consists of about 9 amino acids. In some embodiments, the linker peptide consists of about 8 amino acids. In some embodiments, the linker peptide consists of about 7 amino acids. In some embodiments, the linker peptide consists of about 6 amino acids. In some embodiments, the linker peptide consists of about 5 amino acids. In some embodiments, the linker peptide consists of about 4 amino acids. In some embodiments, the linker peptide consists of about 3 amino acids. In some embodiments, the linker peptide consists of about 2 amino acids.
[0093] In some embodiments, the linker is about 1 to about 10 amino acids in length. In some embodiments, the linker can be about 1 to about 5 amino acids in length. For example, the linker can include 1, 2, 3, 4, or 5 amino acids. In some embodiments, the last amino acid of the linker that contacts the C-terminus of the ARRDC1 protein or variant and the N-terminal domain of the targeting domain is selected from the group consisting of Met, Cys, Thr, Arg, Lys, Ser, Gin, His, Ala, Tyr, Phe, Asn, Trp, Val, Leu, Asp, He, Gly, Glu, and Pro.
[0094] In some embodiments, the linker peptide can be any linker peptide known to one of skill in the art. In some embodiments, the linker peptide has the amino acid sequence of GGGGS (SEQ ID NO:49). In some embodiments, the linker peptide has the amino acid sequence of (GGGGS)2 (SEQ ID NO:50). In some embodiments, the linker peptide has the amino acid sequence of (GGGGS)3 (SEQ ID NO:51). In some embodiments, the linker peptide has the amino acid sequence of (GGGGS)4 (SEQ ID NO:52). In some embodiments, the linker peptide has the amino acid sequence of (Gly)8 (SEQ ID NO:53). In some embodiments, the linker peptide has the amino acid sequence of (Gly)6 (SEQ ID NO:54). In some embodiments, the linker peptide has the amino acid sequence of EAAAK (SEQ ID NO:55). In some embodiments, the linker peptide has the amino acid sequence of (EAAAK)2 (SEQ ID NO:56). In some embodiments, the linker peptide has the amino acid sequence of (EAAAK)3 (SEQ ID NO:57). In some embodiments, the linker peptide has the amino acid sequence of A(EAAAK)4ALEA(EAAAK)4A (SEQ ID NO:58). In some embodiments, the linker peptide has the amino acid sequence of PAPAP (SEQ ID NO:59). In some embodiments, the linker peptide has the amino acid sequence of AEAAAKEAAAKA (SEQ ID NO:60). In some embodiments, the linker peptide has the amino acid sequence of (Ala-Pro) nwhere n is 5 (SEQ ID NO:61), 6 (SEQ ID NO:91), 7 (SEQ ID NO:92), 8 (SEQ ID NO:93), 9 (SEQ ID NO:94), 10 (SEQ ID NO:95), 11 (SEQ ID NO:96), 12 (SEQ ID NO:97), 13 (SEQ ID NO:98), 14 (SEQ ID NO:99), 15 (SEQ ID NO:100), 16 (SEQ ID NO:101), or 17 (SEQ ID NO:102). In some embodiments, the linker peptide is a disulfide. In some embodiments, the linker peptide has an amino acid sequence of VSQTSKLTRAETVFPDV (SEQ ID NO:62). In some embodiments, the linker peptide has an amino acid sequence of PLGLWA (SEQ ID NO:63). In some embodiments, the linker peptide has an amino acid sequence of RVLAEA (SEQ ID NO:64). In some embodiments, the linker peptide has an amino acid sequence of EDVVCCSMSY (SEQ ID NO:65). In some embodiments, the linker peptide has an amino acid sequence of GGIEGRGS (SEQ ID NO:66). In some embodiments, the linker peptide has an amino acid sequence of TRHRQPRGWE (SEQ ID NO:67). In some embodiments, the linker peptide has an amino acid sequence of AGNRVRRSVG (SEQ ID NO:68). In some embodiments, the linker peptide has an amino acid sequence of RRRRRRRRR (SEQ ID NO:69). In some embodiments, the linker peptide has an amino acid sequence of GFLG (SEQ ID NO:70). In some embodiments, the linker peptide has an amino acid sequence of LE (SEQ ID NO:71). In some embodiments, the linker peptide has an amino acid sequence of KESGSVSSEQLAQFRSLD (SEQ ID NO:72). In some embodiments, the linker peptide has an amino acid sequence of EGKSSGSGSESKST (SEQ ID NO:73). In some embodiments, the linker peptide has an amino acid sequence of GSAGSAAGSGEF (SEQ ID NO:74). In some embodiments, the linker peptide has an amino acid sequence of (XP) n(SEQ ID NO:75), where n is an integer greater than 0. In some embodiments, the linker peptide has an amino acid sequence of LEAGCKNFFPRSFTSCGSLE (SEQ ID NO:76). In some embodiments, the linker peptide has an amino acid sequence of CRRRRRREAEAC (SEQ ID NO:77).
[0095] In some embodiments, the linker peptide mimics the sequence of a peptide substrate that is the target of a protease, such that the linker peptide can be fully recognized by the protease active site. In some embodiments, the linker is non-immunogenic. In some embodiments, the linker peptide comprises an α-helical structure.
[0096] In some embodiments, the linker peptide comprises a protease cleavage site. In some embodiments, the protease cleavage site is a Furin site or a variant thereof. In some embodiments, the linker peptide has an amino acid sequence of RXRR (SEQ ID NO: 78) or RXKR (SEQ ID NO: 103). In some embodiments, the linker peptide has an amino acid sequence of TRHRQPRGWEQL (SEQ ID NO: 79). In some embodiments, the linker peptide has an amino acid sequence of RRRRRRRRR (SEQ ID NO: 80). In some embodiments, the linker peptide has an amino acid sequence of TRHRQPRGWE (SEQ ID NO: 81). In some embodiments, the linker peptide has an amino acid sequence of AGNRVRRSVG (SEQ ID NO: 82). In some embodiments, the linker peptide has an amino acid sequence of RHRQPRGWEQL (SEQ ID NO: 83). In some embodiments, the protease cleavage site comprises a Furin cleavage site.
[0097] In some embodiments involving a linker peptide comprising a protease cleavage site, the protease cleavage site is a human immunodeficiency virus-1 (HIV-1) protease cleavage site. In some embodiments, the linker peptide comprises the amino acid sequence of SQNYIVQ (SEQ ID NO: 84) or SQNPIVQ (SEQ ID NO: 104). In some embodiments, the linker peptide has the amino acid sequence of NFSQNYIVQTG (SEQ ID NO: 85) or NFSQNPIVQTG (SEQ ID NO: 105). In some embodiments involving a linker peptide comprising a protease cleavage site, the protease cleavage site is a tobacco etch virus (TEV) protease cleavage site. In some embodiments, the linker peptide comprises the amino acid sequence of ENLYFQ (SEQ ID NO: 86) or ENLYFG (SEQ ID NO: 106). In some embodiments, the linker peptide comprises the amino acid sequence of ENLYFQ (SEQ ID NO: 87) or ENLYFS (SEQ ID NO: 107). In some embodiments, the linker peptide comprises the amino acid sequence of GGGSGGGGSGGGGSENLYFQGGGGSGGGGSGGGGGS (SEQ ID NO: 88) or GGGSGGGGSGGGGGSENLYFGGGGGSGGGGSGGGGS (SEQ ID NO: 108). In some embodiments, the linker peptide comprises the amino acid sequence of GGGSGGGGSGGGGGSENLYFQGGGGSGGGGSGGGGGS (SEQ ID NO: 89) or GGGSGGGGSGGGGGSENLYFSGGGGSGGGGSGGGGGS (SEQ ID NO: 109).
[0098] ARMM In some aspects, the present disclosure relates to a microvesicle comprising an ARRDC1 fusion protein disclosed herein. The arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicle (ARMM) disclosed herein comprises a lipid bilayer and an ARRDC1 fusion protein or variant thereof. In some embodiments, such an ARMM is isolated from a subject, a biological sample, or a cell culture. In some embodiments, the ARMM is synthetically prepared. Methods for producing and / or isolating an ARMM can be found in U.S. Pat. Nos. 9,737,480 and 9,816,080, which are incorporated herein by reference in their entirety. In some embodiments, the ARMM further comprises a fusion RNA, the fusion RNA comprising an RNA sequence that binds to the RNA-binding protein of the ARRDC1 fusion protein, and an expression sequence that encodes a ubiquitin ligase or an aptamer. The RNA sequence can be any of the binding RNAs disclosed herein. In some embodiments, the RNA sequence is a TAR element. In some embodiments, the TAR element is a bovine immunodeficiency virus (BIV) TAR. In some embodiments, the RNA sequence is a variant of a TAR element. In some embodiments, the RNA sequence is a Rev response element (RRE) or a variant thereof. In some embodiments, the RNA sequence is an MS2 RNA. In some embodiments, the RNA sequence is an RNA that specifically binds to a P22 N protein (e.g., P22 N from a bacteriophage), or a variant thereof. In some embodiments, the RNA sequence is an RNA that specifically binds to a λ N protein (e.g., λ N from a bacteriophage), or a variant thereof. In some embodiments, the RNA sequence is an RNA that specifically binds to a φ21 N protein (e.g., φ21 N from a bacteriophage), or a variant thereof. In some embodiments, the RNA sequence is an RNA that specifically binds to an HIV-1 nucleocapsid protein (e.g., nucleocapsid from HIV-1), or a variant thereof. In some embodiments, the RNA sequence is a naturally occurring RNA. In some embodiments, the RNA sequence is a non-naturally occurring RNA.In some embodiments, the RNA sequence is synthetically produced RNA.
[0099] In some embodiments, the ubiquitin ligase is Trim21, its variant or fragment.The expression sequence of Trim21, such as Trim21 mRNA, is fused to the RNA sequence that binds to the RNA binding protein of ARRDC1 fusion protein.In some embodiments, the RNA sequence is directly fused to the expression sequence.In some embodiments, the RNA sequence is fused to the expression sequence by a linker.
[0100] In some embodiments, the ARMM further comprises a TSG101 protein or a fragment thereof. In some embodiments, the TSG101 protein fragment comprises a TSG101 UEV domain. In some embodiments, the ARMM further comprises a cell surface protein (e.g., a receptor) or a cytoplasmic protein (e.g., an enzyme). In some embodiments, the ARMM further comprises an integrin, a receptor tyrosine kinase, a G protein-coupled receptor, or a membrane-bound immunoglobulin. In some embodiments, the microvesicle comprises an integrin selected from the group consisting of α1β1, α2β1, α4β1, α5β1, α6β1, αLβ2, αMβ2, αIIbβ3, αVβ3, αVβ5, αVβ6, and α6β4 integrin; EGF receptor (ErbB family), insulin receptor, PDGF receptor, FGF receptor, VEGF receptor, HGF receptor, Trk receptor, Eph receptor, AXL40 receptor, LTK receptor, TIE receptor, ROR receptor, DDR receptor, RET receptor , a receptor tyrosine kinase selected from the group consisting of KLG receptor, RYK receptor, and MuSK receptor; a G protein-coupled receptor selected from the group consisting of rhodopsin-like receptor, secretin receptor, metabotropic glutamate / pheromone receptor, cyclic AMP receptor, frizzled / smoothed receptor, CXCR4, CCRS, or β-adrenergic receptor; and / or an exocyst protein listed in Table 1 selected from EXOC7, EXOC8, EXOC1, and EXOC2. Additional proteins can be found in U.S. Pat. No. 9,737,480, which is incorporated by reference in its entirety.
[0101] In some embodiments, the ARMM does not include exosome biomarkers. In some embodiments, the ARMM does not include one or more exosome biomarkers. In some embodiments, the exosome biomarkers are selected from the group consisting of CD63, Lamp-1, Lamp-2, CD9, HSPA8, GAPDH, CD81, SDCBP, PDCD6IP, ENO1, ANXA2, ACTB, YWHAZ, H5P90AA1, ANXAS, EEF1A1, YWHAE, PPIA, MSN, CFL1, ALDOA, PGK1, EEF2, ANXA1, PKM2, HLA-DRA, and YWHAB.
[0102] In some embodiments, the ARMM comprises an agent, such as, for example, a protein, a nucleic acid, or a small molecule. In some embodiments, the agent is conjugated to an ARRDC1 protein or an ARRDC1 variant. In some embodiments, the nucleic acid is an RNA. In some embodiments, the nucleic acid is an RNAi agent. In some embodiments, the nucleic acid is a coding RNA, a non-coding RNA, an antisense RNA, an mRNA, a small RNA, an siRNA, an shRNA, a microRNA, a snRNA, a snoRNA, a lincRNA, a structural RNA, a ribozyme, or a precursor thereof. In some embodiments, the nucleic acid is a DNA. In some embodiments, the nucleic acid comprises a retrotransposon sequence, a LINE sequence, a SINE sequence, a composite SINE sequence, or an LTR-retrotransposon sequence. In some embodiments, the nucleic acid encodes a protein. In some embodiments, the agent comprises a detectable label. In some embodiments, the agent is a therapeutic agent. In some embodiments, the agent is a drug approved for human or veterinary use by a government agency. In some embodiments, the agent is a cytotoxic agent. In some embodiments, the agent is a protein. In some embodiments, the agent is a transcription factor, a transcription repressor, a fluorescent protein, a kinase, a phosphatase, a protease, a ligase, or a recombinase. In some embodiments, the agent is a small molecule. In some embodiments, the agent is covalently attached to the ARRDC1 protein or a variant thereof, or another protein of the ARMM. In some embodiments, the agent is conjugated to the ARRDC1 protein or a variant thereof, or another protein via a linker. In some embodiments, the linker is a cleavable linker. In some embodiments, the linker comprises a protease recognition site. In some embodiments, the linker is a UV-cleavable linker. In certain embodiments, the linker is cleaved under certain conditions, such as pH, redox conditions, etc. In some embodiments, the diameter of the microvesicle is about 30 nm to about 500 nm.
[0103] Nucleic acid sequences and expression constructs Some aspects of the present disclosure provide a nucleic acid sequence encoding any of the fusion proteins described herein. For example, the nucleic acid sequence encodes an ARRDC1 fusion protein or variant thereof that is fused to a non-enzymatic targeting domain that recruits a target protein. The targeting domain may be fused to the N-terminus of the ARRDC1 protein or variant thereof. The targeting domain may be fused to the C-terminus of the ARRDC1 protein or variant thereof. In some embodiments, the ARRDC1 protein or variant thereof is fused to the targeting domain by a linker as disclosed herein. The linker may be a cleavable linker. For example, the linker may include a protease cleavage site, such as a furin cleavage site.
[0104] In some aspects, the present specification provides an expression construct comprising the nucleotide sequence encoding the ARRDC1 fusion protein disclosed herein operably linked to a heterologous promoter.Such an expression construct is useful for producing the ARRDC1 fusion protein disclosed herein in cells, thereby inducing or increasing the production of ARMM in cells.The ARMM produced by the cell expressing such ARRDC1 fusion protein comprises the ARRDC1 fusion protein encoded by the expression construct in some embodiments.
[0105] Some embodiments of the present disclosure further provide additional nucleic acid sequences encoding additional molecules intended for expression in parallel with the fusion proteins disclosed herein, such additional molecules including RNA polymers comprising an RNA sequence that binds to said RNA binding protein and an expression sequence that encodes (i) a ubiquitin ligase, such as Trim21, or (b) an aptamer that specifically binds to a target protein.
[0106] Microvesicle-producing cells In some aspects, the present disclosure provides a microvesicle producing cell comprising a recombinant expression construct encoding the ARRDC1 fusion protein disclosed herein under the control of a heterologous promoter. In some embodiments, the microvesicle producing cell further comprises a recombinant expression construct encoding the fusion RNA disclosed herein under the control of a heterologous promoter, the fusion RNA comprising (i) an RNA sequence that binds to said RNA binding protein, and (ii) an expression sequence that encodes (a) a ubiquitin ligase or (b) an aptamer that specifically binds to a target protein. In some embodiments, the RNA sequence is a TAR element. In some embodiments, the TAR element is a bovine immunodeficiency virus (BIV) TAR. In some embodiments, the RNA sequence is a variant of a TAR element. In some embodiments, the RNA sequence is a Rev response element (RRE) or a variant thereof. In some embodiments, the RNA sequence is an MS2 RNA. In some embodiments, the RNA sequence is an RNA that specifically binds to a P22 N protein (e.g., P22 N from a bacteriophage), or a variant thereof. In some embodiments, the RNA sequence is an RNA that specifically binds to λ N protein (e.g., λ N from a bacteriophage), or a variant thereof. In some embodiments, the RNA sequence is an RNA that specifically binds to φ21 N protein (e.g., φ21 N from a bacteriophage), or a variant thereof. In some embodiments, the RNA sequence is an RNA that specifically binds to HIV-1 nucleocapsid protein (e.g., nucleocapsid from HIV-1), or a variant thereof. In some embodiments, the RNA sequence is a natural RNA. In some embodiments, the RNA sequence is a non-natural RNA. In some embodiments, the RNA sequence is a synthetically produced RNA. In some embodiments, the ubiquitin ligase is Trim21. An expressed sequence of Trim21, such as Trim21 mRNA, is fused to an RNA sequence that binds to the RNA-binding protein of the ARRDC1 fusion protein. In some embodiments, the RNA sequence is directly fused to the expressed sequence.In some embodiments, the RNA sequence is fused to the expression sequence by a linker.
[0107] In some embodiments, expression of the ARRDC1 fusion protein induces or increases the cell's production of ARMM. In some embodiments, the cell expresses or contains in its cytoplasm or in its cell membrane an agent contained in the ARMM produced by the cell. In some embodiments, the cell is a eukaryotic cell. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a human cell. In some embodiments, the cell further comprises a recombinant expression construct encoding an RNAi agent. In some embodiments, the RNAi agent is a nucleic acid. In some embodiments, the nucleic acid is a non-coding RNA, an antisense RNA, a small RNA, an siRNA, an shRNA, a microRNA, a snRNA, a snoRNA, a lincRNA, or a precursor thereof. In some embodiments, the cell further comprises a recombinant expression construct encoding a ribozyme.
[0108] In some embodiments, the cells have a reduced expression level of ubiquitin ligase compared to wild-type cells. In some embodiments, the cells are genetically engineered to have a reduced expression level of ubiquitin ligase compared to wild-type cells. In some embodiments, the expression of ubiquitin ligase in the cells is reduced or inhibited by small interfering RNA (siRNA), CRISPR, or other gene editing tools known to those skilled in the art. In some embodiments, the expression of ubiquitin ligase in the cells is reduced or inhibited by small molecule inhibitors known to those skilled in the art. In some embodiments, the activity of ubiquitin ligase in the cells is reduced or inhibited. In some embodiments, the activity of ubiquitin ligase in the cells is reduced or inhibited by small interfering RNA (siRNA), CRISPR, or other gene editing tools known to those skilled in the art. In some embodiments, the activity of ubiquitin ligase in the cells is reduced or inhibited by small molecule inhibitors known to those skilled in the art. In some embodiments, the amount or activity of ubiquitin ligase expressed in the cells is minimal so as not to substantially prevent the production of ARMM in the cells. In some embodiments, the cell lacks ubiquitin ligase. That is, the expression level of ubiquitin ligase cannot be detected by tools available in the art. In some embodiments, the cell lacks at least one ubiquitin ligase. In some embodiments, the cell lacks one or more ubiquitin ligases. The ubiquitin ligase can be selected from the group consisting of HECW2, HECW1, WWPL, WWP2, NEDD4-1, NEDD4-2, NEDD4L, SMURFL, SMURF2, SMURF1, ITCH, NEDL1, and NEDL2.
[0109] In some embodiments, the cells have a reduced expression level of the target protein compared to wild-type cells. In some embodiments, the cells are genetically engineered to have a reduced expression level of the target protein compared to wild-type cells. In some embodiments, the expression of the target protein in the cells is reduced or inhibited by small interfering RNA (siRNA), CRISPR, or other gene editing tools known to those skilled in the art. In some embodiments, the expression of the target protein in the cells is reduced or inhibited by small molecule inhibitors known to those skilled in the art. In some embodiments, the amount of the target protein expressed in the cells is minimal so as not to substantially prevent the production of ARMM in the host cell. In some embodiments, the cells lack the target protein. That is, the expression level of the target protein is not detectable by tools available in the art.
[0110] Target Protein The ARRDC1 fusion protein or ARMM disclosed herein can recruit target proteins for ubiquitination and degradation. Any protein that can be recruited and / or bound to the targeting domain and acted upon or degraded by ubiquitin ligase can be a target protein. In general, target proteins may include, for example, structural proteins, receptors, enzymes, cell surface proteins, proteins associated with the integral function of a cell, including proteins involved in catalytic activity, aromatase activity, motility activity, helicase activity, metabolic processes (anabolic and catabolic), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulatory activity, signal transduction activity, structural molecule activity, binding activity (proteins, lipids carbohydrates), receptor activity, cell motility, membrane fusion, cell communication, control of biological processes, development, cell differentiation, response to stimuli, behavioral proteins, cell adhesion proteins, proteins involved in cell death, transport (including protein transporter activity, nuclear transport, ion transporter activity, channel transporter activity, carrier activity, permease activity, secretion activity, electron transporter activity, pathogenesis, chaperone regulatory activity, nucleic acid binding activity, transcription regulator activity, extracellular organization and biogenesis activity, translation regulator activity). Proteins of interest can include proteins from eukaryotes and prokaryotes, including humans, as targets for drug therapy, other animals, including livestock animals, microorganisms and plants for determining targets for antibiotics and other antimicrobial agents, and even viruses, among many others.
[0111] The target protein can be any protein that is desired to be degraded or reduced in the target cell. The target protein can be an enzyme, a transcription factor, a developmental regulator, a growth factor, a nuclease, a recombinase, a reprogramming factor, or a membrane-associated protein, a protein product of a tumor promoter or an oncogene, a developmental regulator, a growth factor, a metastasis promoter, an anti-apoptotic protein, a membrane-associated protein, a transmembrane receptor, an enzyme, or a pathogenic protein (e.g., a pathogenic variant or mutant of a normal protein, or a protein that has a pathogenic or deleterious activity as a result of post-translational modification). The target protein can be an antigen or a ligand. The target protein can be a protein derived from a cancer cell. The protein derived from a cancer cell can be an oncogenic protein, or a signaling mediator of an abnormal cell proliferation pathway, whose degradation reduces the abnormal cell proliferation.
[0112] The target protein may be derived from a gene that has undergone an amplification, translocation, deletion, or inversion event that causes or is caused by a medical disorder.In certain embodiments, the target protein is post-translationally modified by one or a combination of phosphorylation, acetylation, acylation including propionylation and crotylation, N-linked glycosylation, amidation, hydroxylation, methylation, polymethylation, O-linked glycosylation, pyroglutamoylation, myristoylation, farnesylation, geranylation, ubiquitination, sumoylation, or sulfation that causes or is caused by a medical disorder.
[0113] In some embodiments, the target protein is not a druggable protein in the classical sense, in that it does not have a binding pocket or active site that can be inhibited or otherwise bound, and cannot be readily allosterically regulated. In some embodiments, the target protein is a druggable protein in the classical sense, but for therapeutic purposes, degradation of the protein is preferred over inhibition.
[0114] The target protein is recruited with a targeting domain. The targeting domain may be a ligand for the target protein. The targeting domain may bind to the target protein non-covalently.
[0115] The target protein may be any amino acid sequence to which the targeting domain of the fusion protein disclosed herein can bind and subsequently be degraded to provide a beneficial therapeutic effect in vivo. In some embodiments, the target protein is a non-endogenous peptide, e.g., a peptide derived from a pathogen or a toxin. In some embodiments, the target protein may be an endogenous protein that mediates a disorder. The endogenous protein may be either a normal or abnormal form of the protein. For example, the target protein may be a mutant protein identified in cancer cells, or a protein in which, for example, a partial or complete gain or loss of function is encoded by a nucleotide polymorphism. In some embodiments, the targeting domain of the fusion protein disclosed herein targets an abnormal form of the protein rather than the normal form of the protein. In some embodiments, the target protein may mediate an inflammatory disorder, or an immune disorder, including an autoimmune disorder. In some embodiments, the target protein is a non-endogenous protein derived from a virus, such as, but not limited to, HIV, HBV, HCV, RSV, HPV, CMV, flavivirus, pestivirus, coronavirus, or noroviridae. In some embodiments, the target protein is a non-endogenous protein from bacteria, which may be, for example, gram-positive bacteria, gram-negative bacteria, or other, and may be a drug-resistant type of bacteria. In some embodiments, the target protein is a non-endogenous protein from fungi. In some embodiments, the target protein is a non-endogenous protein from prions. In some embodiments, the target protein is a protein from eukaryotic pathogens, such as protozoa, helminths, etc.
[0116] In some embodiments, target protein can mediate chromatin structure and function.Target protein can mediate epigenetic effects such as DNA methylation or covalent modification of histone.One example is histone deacetylase.In some embodiments, target protein can be bromodomain-containing protein, which is a reader of lysine acetylation.
[0117] In some embodiments, the target protein may be a structural protein, a receptor, an enzyme, a cell surface protein, a protein involved in apoptosis signaling, an aromatase, a helicase, a mediator of a metabolic process (anabolic or catabolic), an antioxidant, a protease, a kinase, an oxidoreductase, a transferase, a hydrolase, a lyase, an isomerase, a ligase, an enzyme regulator, a signal transduction factor, a structural molecule, a binding activity (protein, lipid carbohydrate), a cell motility protein, a membrane fusion protein, a cell communication mediator, a regulator of a biological process, a behavioral protein, a cell adhesion protein, a protein involved in cell death, or a protein involved in transport (including protein transporter activity, nuclear transport, ion transporter, channel transporter, carrier activity, permease, secretase or secretion mediator, electron transporter, chaperone regulator, nucleic acid binding, transcription regulator, extracellular organization and biosynthesis regulator, and translation regulator).
[0118] In some embodiments, the target protein is a modulator of a signal transduction cascade associated with a known disease state.In some embodiments, the target protein mediates a disorder by a mechanism other than the modulation of a signal transduction cascade.Any protein in a eukaryotic system or a microbial system, including a virus, a bacterium, or a fungus, is a target for proteasomal degradation using the fusion protein or ARMM disclosed herein, as described elsewhere herein.The target protein is a eukaryotic protein, and in some embodiments, can be a human protein.
[0119] In some embodiments, the target protein is RXR, DHFR, Hsp90, kinase, HDM2, MDM2, BET bromodomain-containing protein, HDAC, IDH1, Mcl-1, human lysine methyltransferase, nuclear hormone receptor, aryl hydrocarbon receptor (AHR), RAS, RAF, FLT, SMARC, KSR, NF2L, CTNB, CBLB, or BCL.
[0120] In some embodiments, the target protein is selected from EGFR, FLT3, RAF1, SMRCA2, KSR1, NF2L2, CTNB1, CBLB, BCL6, and RASK.
[0121] In some embodiments, the target protein is an EGFR ligand, a FLT3 ligand, a RAF1 ligand, a SMRCA2 ligand, a KSR1 ligand, a NF2L2 ligand, a CTNB1 ligand, a CBLB ligand, a BCL6 ligand, or a RASK ligand.
[0122] The ARRDC1 fusion proteins or ARMM disclosed herein can be used to treat a wide range of disease states and / or conditions, including any disease state and / or condition in which a protein is dysregulated and in which the patient would benefit from degradation of the protein.
[0123] For example, a target protein can be selected that is a known target of a human therapeutic agent, which can be used as a targeting domain when fused to an ARRDC1 protein or variant thereof according to the present disclosure. These include, for example, B7.1 and B7, TINFR1m, TNFR2, NADPH oxidase, Bcl2 / Bax and other partners of the apoptosis pathway, C5a receptor, HMG-CoA reductase, PDE V phosphodiesterase type, PDE IV phosphodiesterase type 4, PDE I, PDEII, PDEIII, squalene cyclase inhibitors, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclooxygenase 1, cyclooxygenase 2, 5HT receptors, dopamine receptors, G proteins, e.g. Gq, histamine receptors, 5-lipoxygenase, tryptase serine protease, thymidylate synthase, purine nucleoside phosphorylase, GAPDH trypanosoma, glycogen phosphorylase, carbonic anhydrase, chemokine receptors, JAW STAT, RXR and similar, HIV 1 protease, HIV 1 integrase, influenza, neuraminidase, hepatitis B reverse transcriptase, sodium channel, multidrug resistance (MDR), protein P-glycoprotein (and MRP), tyrosine kinase, CD23, CD124, tyrosine kinase p56 lck, CD4, CD5, IL-2 receptor, IL-1 receptor, TNF-αR, ICAM1, Cat+ channel, VCAM, VLA-4 integrin, selectins, CD40 / CD40L, neurokinins and receptors, inosine monophosphate dehydrogenase, p38 MAP kinase, Ras / Raf / MER / ERK pathway, interleukin-1 converting enzyme, caspases, HCV, NS3 protease, HCV NS3RNA helicase, glycinamide ribonucleotide formyltransferase, rhinovirus 3C protease, herpes simplex virus-1 (HSV-I), protease, cytomegalovirus (CMV) protease, poly(ADP-ribose) polymerase, cyclin-dependent kinase, vascular endothelial growth factor, oxytocin receptor, microsomal transfer protein inhibitor, bile acid transport inhibitor, 5α-reductase inhibitor, angiotensin 11, glycine receptor, noradrenaline reuptake receptor, endothelin receptor, neuropeptide Y and receptor, estrogen Proteins that may be used to restore function in polygenetic diseases include cytoplasmic receptors, androgen receptors, adenosine receptors, adenosine kinase and AMP deaminase, purinergic receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2X1-7), farnesyltransferase, geranylgeranyltransferase, NGF receptor TrkA, beta amyloid, tyrosine kinase Flk-IIKDR, vitronectin receptor, integrin receptor, Her-2 / neu, telomerase inhibition, cytoplasmic phospholipase A2 and EGF receptor tyrosine kinase. Additional protein targets include, for example, ecdysone 20-monooxygenase, GABA-gated chloride channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel, and chloride channel ion channel. Yet further target proteins include acetyl-CoA carboxylase, adenylosuccinate synthase, protoporphyrinogen oxidase, and enolpyruvylshikimate phosphate synthase.
[0124] In some embodiments, the target protein is a tyrosine kinase (e.g., but not limited to, AATK, ABL, ABL2, ALK, AXL, BLK, BMX, BTK, CSF1R, CSK, DDR1, DDR2, EGFR, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHA10, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FER, FES, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1, FLT3, FLT4, FRK, FYN, GSG2, HCK, IGF1R, ILK, INSR, INSRR, IRAK4, ITK , JAK1, JAK2, JAK3, KDR, KIT, KSR1, LCK, LMTK2, LMTK3, LTK, LYN, MATK, MERTK, MET, MLTK, MST1R, MUSK, NPR1, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PLK4, PTK2, PTK2B, PTK6, PTK7, RET, ROR1, ROR2, ROS1, RYK, SGK493, SRC, SRMS, STYK1, SYK, TEC, TEK, TEX14, TIE1, TNK1, TNK2, TNNI3K, TXK, TYK2, TYRO3, YES1, or ZAP70).
[0125] In some embodiments, the target protein may be, but is not limited to, a serine / threonine kinase (e.g., casein kinase 2, protein kinase A, protein kinase B, protein kinase C, Raf kinase, CaM kinase, AKT1, AKT2, AKT3, ALK1, ALK2, ALK3, ALK4, Aurora A, Aurora B, Aurora C, CHK1, CHK2, CLK1, CLK2, CLK3, DAPK1, DAPK2, DAPK3, DMPK, ERK1, ERK2, ERK5, GCK, GSK3, HIPK, KHS1, LKB1, LOK, The targeting domain is derived from a kinase that can bind or that binds, including MAPKAPK2, MAPKAPK, MNK1, MSSK1, MST1, MST2, MST4, NDR, NEK2, NEK3, NEK6, NEK7, NEK9, NEK11, PAK1, PAK2, PAK3, PAK4, PAK5, PAK6, PIM1, PIM2, PLK1, RIP2, RIP5, RSK1, RSK2, SGK2, SGK3, SIK1, STK33, TAO1, TAO2, TGF-β, TLK2, TSSK1, TSSK2, ULK1, or ULK2).
[0126] In some embodiments, the target protein is derived from a kinase to which the targeting domain can bind or binds, including, but not limited to, a cyclin-dependent kinase, e.g., CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, or CDK13.
[0127] In some embodiments, the target protein is derived from a kinase to which the targeting domain can bind or binds, including, but not limited to, leucine-rich repeat kinase (e.g., LRRK2).
[0128] In some embodiments, the target protein is derived from a kinase to which the targeting domain can bind or which binds, including, but not limited to, lipid kinases (e.g., PIK3CA, PIK3CB) or sphingosine kinases (e.g., S1P).
[0129] In some embodiments, the target protein is derived from a BET bromodomain-containing protein to which the targeting domain can bind or binds, including, but not limited to, ASH1L, ATAD2, BAZ1A, BAZ1B, BAZ2A, BAZ2B, BRD1, BRD2, BRD3, BRD4, BRD5, BRD6, BRD7, BRD8, BRD9, BRD10, BRDT, BRPF1, BRPF3, BRWD3, CECR2, CREBBP, EP300, FALZ, GCN5L2, KIAA1240, LOC93349, MLL, PB1, PCAF, PHIP, PRKCBP1, SMARCA2, SMARCA4, SP100, SP110, SP140, TAF1, TAF1L, TIF1a, TRIM28, TRIM33, TRIM66, WDR9, ZMYND11, and MLL4. In certain embodiments, the BET bromodomain-containing protein is BRD4.
[0130] In some embodiments, the target protein is derived from a nuclear protein to which the targeting domain can bind or which binds, including, but not limited to, BRD2, BRD3, BRD4, antennapedia homeodomain protein, BRCA1, BRCA2, CCAAT-enhanced binding protein, histones, polycomb group proteins, high mobility group proteins, telomere binding proteins, FANCA, FANCD2, FANCE, FANCF, hepatocyte nuclear factor, Mad2, NF-κB, nuclear receptor coactivator, CREB binding protein, p55, p107, p130, Rb protein, p53, c-fos, c-jun, c-mdm2, c-myc, and c-rel.
[0131] In some embodiments, the target protein is a member of the retinoid X receptor (RXR) family and the disorder being treated is a neuropsychiatric or neurodegenerative disorder. In some embodiments, the target protein is a member of the retinoid X receptor (RXR) family and the disorder being treated is schizophrenia.
[0132] In some embodiments, the target protein is dihydrofolate reductase (DHFR) and the disorder being treated is cancer. In certain embodiments, the target protein is dihydrofolate reductase (DHFR) and the disorder being treated is microbial. In some embodiments, the target protein is dihydrofolate reductase from bacillus anthracis (BaDHFR) and the disorder being treated is anthrax. In some embodiments, the target protein is heat shock protein 90 (HSP90) and the disorder being treated is cancer. In some embodiments, the target protein is a kinase or phosphatase and the disorder being treated is cancer. In some embodiments, the target protein is HDM2 and / or MDM2 and the disorder being treated is cancer. In some embodiments, the target protein is a BET bromodomain-containing protein and the disorder being treated is cancer. In some embodiments, the target protein is a lysine methyltransferase and the disorder being treated is cancer. In some embodiments, the target protein belongs to the RAF family and the disorder being treated is cancer. In some embodiments, the target protein belongs to the FKBP family and the disorder to be treated is an autoimmune disorder. In some embodiments, the target protein belongs to the FKBP family and the disorder to be treated is organ rejection. In some embodiments, the target protein belongs to the FKBP family and the compound is administered prophylactically to prevent organ failure. In some embodiments, the target protein is an androgen receptor and the disorder to be treated is cancer. In some embodiments, the target protein is an estrogen receptor and the disorder to be treated is cancer. In some embodiments, the target protein is a viral protein and the disorder to be treated is a viral infection. In some embodiments, the target protein is a viral protein and the disorder to be treated is HIV, HPV, or HCV. In some embodiments, the target protein is an AP-1 or AP-2 transcription factor and the disorder to be treated is cancer. In some embodiments, the target protein is HIV protease and the disorder to be treated is HIV infection. In some embodiments, the target protein is HIV integrase and the disorder to be treated is HIV infection.In some embodiments, the target protein is HCV protease and the disorder being treated is HCV infection. In some embodiments, the treatment is prophylactic and the target protein is a viral protein. In some embodiments, the target protein is a member of the histone deacetylase (HDAC) family and the disorder is a neurodegenerative disorder. In some embodiments, the target protein is a member of the histone deacetylase (HDAC) family and the disorder is Huntington's disease, Parkinson's disease, Kennedy's disease, amyotrophic lateral sclerosis, Rubinstein-Taybi syndrome, or stroke.
[0133] In some embodiments, the target protein referred to herein is named by the gene that expresses it.When a gene is referred to as a target protein, those skilled in the art will understand that the protein encoded by the gene is the target protein.Additional target proteins can be found in US Patent Publication No. 2019 / 0076539, which is incorporated herein by reference in its entirety.
[0134] Targeting Domains In certain aspects, the targeting domain is a ligand that is covalently or non-covalently bound to the target protein selected for proteasomal degradation by the fusion protein. The targeting domain is a small molecule or moiety (e.g., peptide, nucleotide, antibody, antibody fragment, aptamer, biomolecule, or other chemical structure) that binds to the target protein, and the target protein is a mediator of disease in the host, as detailed above. In some embodiments, the targeting domain is a non-enzymatic targeting domain. In some embodiments, the targeting domain comprises an antibody, an antibody fragment, or an antibody derivative. In some embodiments, the targeting domain comprises an antigen.
[0135] In some embodiments, the targeting domain binds to endogenous proteins targeted for degradation as a means of achieving a therapeutic effect on the host. Exemplary targeting domains include RXR ligands, DHFR ligands, MerTK ligands, IDH1 ligands, Mcl-1 ligands, SMRCA2 ligands, EGFR ligands, RAF ligands, and cRAF ligands. In some embodiments, the targeting domain is an aryl hydrocarbon receptor (AHR) ligand. Non-limiting examples of AHR ligands include apigenin, SR1, LGC006, and analogs thereof. In some embodiments, the targeting domain is a MerTK or Mer targeting domain. In some embodiments, the targeting domain is an EGFR ligand. In some embodiments, the targeting domain is an EGRF ligand selected from afatinib, dacomitinib, neratinib, poziotinib, and canertinib, or derivatives thereof. In some embodiments, the targeting domain is an FLT3 ligand. In some embodiments, the targeting domain is a FLT3 ligand selected from tandutinib, lestaurtinib, sorafenib, midostaurin, quizartinib, and crenolanib. In some embodiments, dabrafenib is a Ubc9 SUMO E2 ligase 5F6D targeting ligand. In some embodiments, dabrafenib is a Tank1 targeting ligand. In some embodiments, the targeting ligand is a SH2 domain of a pp60 Src targeting ligand. In some embodiments, dabrafenib is a Sec7 domain targeting ligand. In some embodiments, the targeting domain is a saposin-B targeting ligand. In some embodiments, the targeting domain is a protein S100-A7 20WS targeting ligand. In some embodiments, the targeting domain is a phospholipase A2 targeting ligand. In some embodiments, the targeting domain is a PHIP targeting ligand. In some embodiments, the targeting domain is a PDZ targeting ligand. In some embodiments, the targeting domain is a PARP15 targeting ligand. In some embodiments, the targeting domain is a PARP14 targeting ligand.In some embodiments, the targeting domain is an MTH1 targeting ligand. In some embodiments, the targeting domain is an mPGES-1 targeting ligand.
[0136] In some embodiments, the targeting domain is a FLAP-5-lipoxygenase activating protein targeting ligand. In some embodiments, the targeting domain is a FA binding protein targeting ligand. In some embodiments, the targeting domain is a BCL2 targeting ligand. In some embodiments, the targeting domain is a NF2L2 targeting ligand. In some embodiments, the targeting domain is a CTNNB1 targeting ligand. In some embodiments, the targeting domain is a CBLB targeting ligand. In some embodiments, the targeting domain is a BCL6 targeting ligand. In some embodiments, the targeting domain is a RASK targeting ligand. In some embodiments, the targeting domain is a TNIK targeting ligand. In some embodiments, the targeting domain is a MEN1 targeting ligand. In some embodiments, the targeting domain is a PI3Ka targeting ligand. In some embodiments, the targeting domain is an IDO1 targeting ligand. In some embodiments, the targeting domain is an MCL1 targeting ligand. In some embodiments, the targeting domain is a PTPN2 targeting ligand. In some embodiments, the targeting domain is a HER2 targeting ligand. In some embodiments, the targeting ligand is an EGFR targeting ligand. In one embodiment, the EGFR targeting ligand is erlotinib (Tarceva), gefitinib (Iressa), afatinib (Gilotrif), rociletinib (CO-1686), osimertinib (Tagrisso), olmutinib (Olita), nactinib (ASP8273), nazartinib (EGF816), PF-06747775 (Pfizer), icotinib ( BPI-2009), neratinib (HKI-272, PB272); avitinib (AC0010), EAI045, tarloxotinib (TH-4000; PR-610), PF-06459988 (Pfizer), tesevatinib (XL647; EXEL-7647; KD-019), transtinib, WZ-3146, WZ8040, CNX-2006, and dacomitinib (PF-00299804, Pfizer).Linkers can be placed on these targeting ligands at any position that does not prevent the ligand from binding to EGFR. In some embodiments, the EGFR targeting ligand binds to the L858R mutant of EGFR. In some embodiments, the EGFR targeting ligand binds to the T790M mutant of EGFR. In some embodiments, the EGFR targeting ligand binds to the C797G mutant or the C797S mutant of EGFR. In some embodiments, the EGFR targeting ligand is selected from erlotinib, gefitinib, afatinib, neratinib, and dacomitinib, and binds to the L858R mutant of EGFR. In some embodiments, the EGFR targeting ligand is selected from osimertinib, rociletinib, olmutinib, nactinib, nazartinib, PF-06747775, icotinib, neratinib, avitinib, tarloxotinib, PF-0645998, tesevatinib, transtinib, WZ-3146, WZ8040, and CNX-2006, and binds to the T790M mutant of EGFR. In some embodiments, the EGFR targeting ligand is EA1045, and binds to the C797G or C797S mutant of EGFR.
[0137] In some embodiments, the target protein and targeting domain pair is selected by screening a library of ligands. Such screening is exemplified in "Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases" by Duong-Ly et al.; Cell Reports 14, 772-781 Feb. 2, 2016.
[0138] In some embodiments, target protein and targeting domain pairs are discovered by screening promiscuous kinase-binding ligands for context-specific degradation.
[0139] Additional targeting domains can be found in U.S. Patent Application Publication No. 2019 / 0076539, which is incorporated by reference in its entirety.
[0140] Indications In some embodiments, the fusion protein or ARMM described herein can also be used in a method of treating a subject in need thereof, comprising administering to the subject in need thereof a therapeutically effective amount of the fusion protein or ARMM described herein.Treatment can be therapeutic, prophylactic or preventative.Treatment includes alleviating, reducing or preventing at least one aspect or symptom of disease, including preventing or curing the disease described herein.
[0141] The disease may be an inflammatory disorder, an autoimmune disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a transplant-related disorder. In some embodiments, the disorder is a proliferative disorder, lupus, or lupus nephritis. Abnormal cell proliferation, particularly hyperproliferation, may occur as a result of a variety of factors, including genetic mutations, infections, exposure to toxins, autoimmune disorders, and benign or malignant tumor induction. There are numerous skin disorders associated with cell hyperproliferation. For example, psoriasis is a benign disease of human skin that is generally characterized by thickened, scaly patches. The disease is caused by hyperproliferation of epidermal cells for unknown reasons. Chronic eczema is also associated with significant hyperproliferation of the epidermis. Other diseases caused by hyperproliferation of skin cells include atopic dermatitis, lichen planus, warts, pemphigus vulgaris, actinic keratosis, basal cell carcinoma, and squamous cell carcinoma. Other hyperproliferative cell disorders include vascular proliferation disorders, fibrotic disorders, autoimmune disorders, graft-versus-host rejection, tumors, and cancers.
[0142] In some embodiments, the proliferative disorder is cancer. Cancers include squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinoma, and renal cell carcinoma, bladder, intestine, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach cancer; leukemia; benign and malignant lymphomas, especially Burkitt's lymphoma and non-Hodgkin's lymphoma; benign and malignant melanoma; myeloproliferative disorders; multiple myeloma, sarcomas, including Ewing's sarcoma, angiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcoma, peripheral neuroepithelioma, synovial sarcoma, glioma, astrocytoma, oligodendroglioma, ependymoma, glioblastoma, including neuroblastoma, ganglioneuroma, ganglioglioma, medulloblastoma, pineal cell tumor, meningioma, meningeal sarcoma, neurofibroma, and Schwannoma; colorectal cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, gastric cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor or teratocarcinoma, T-lineage acute lymphoblastic leukemia (T-ALL), T-lineage lymphoblastic lymphoma (T-LL), peripheral T-cell lymphoma, adult T-cell leukemia, pre-B ALL, pre-B lymphoma, large B-cell lymphoma, Burkitt's lymphoma, B-cell ALL, Philadelphia chromosome positive ALL, or Philadelphia chromosome positive CML.
[0143] The disease state or condition may be a disease caused by a microbial agent or other exogenous agent, such as a virus (non-limiting examples include HIV, HBV, HCV, HSV, HPV, RSV, CMV, Ebola, flavivirus, pestivirus, rotavirus, influenza, coronavirus, EBV, viral pneumonia, drug resistant virus, avian influenza, RNA virus, DNA virus, adenovirus, poxvirus, picornavirus, togavirus, orthomyxovirus, retrovirus or hepadnovirus), bacteria (gram negative, gram positive), fungus, protozoan, helminth, worm, prion, parasite, or other microorganism, or may be a disease state caused by overexpression of a protein, leading to the disease state and / or condition.
[0144] Additional disease states or conditions that may be treated by an ARRDC1 fusion protein or ARMM according to the present disclosure include Alzheimer's disease, amyotrophic lateral sclerosis (Lou Gehrig's disease), anorexia nervosa, anxiety disorder, arteriosclerosis, attention deficit hyperactivity disorder, autism, bipolar disorder, chronic fatigue syndrome, chronic obstructive pulmonary disease, Crohn's disease, coronary heart disease, dementia, depression, type 1 diabetes, type 2 diabetes, epilepsy, Guillain-Barre syndrome, irritable bowel syndrome, lupus, metabolic syndrome, multiple sclerosis, myocardial infarction, obesity, obsessive-compulsive disorder, panic disorder, Parkinson's disease, psoriasis, rheumatoid arthritis, sarcoidosis, schizophrenia, stroke, thromboangiitis obliterans, Tourette's syndrome, and vasculitis.
[0145] Still further disease states or conditions that may be treated by the ARRDC1 fusion proteins or ARMM according to the present disclosure include aceruloplasminemia, achondroplasia type II, achondroplasia, pycnocephaly, Gaucher disease type 2, acute intermittent porphyria, Canavan disease, adenomatous polyposis coli, ALA dehydratase deficiency, adenylosuccinate lyase deficiency, adrenogenital syndrome, adrenoleukodystrophy, ALA-D porphyria, ALA dehydratase deficiency, alkaptonuria, Alexander disease, alkaptonuric ochronosis, alpha 1-antitrypsin deficiency, alpha 1-proteinase ... Inase inhibitors, emphysema, amyotrophic lateral sclerosis, Alström syndrome, Alexander disease, hereditary enamel hypoplasia, ALA dehydratase deficiency, Anderson-Fabry disease, androgen insensitivity syndrome, anemia, diffuse angiokeratoma corporis, retinal angiomatosis (von Hippel-Lindau disease), Apert syndrome, arachnodactyly (Marfan syndrome), Stickler syndrome, congenital multiple joint laxity (Ehlers-Danlos syndrome #arthralgia type), ataxia-telangiectasia, Rett syndrome, primary pulmonary hypertension, Sandhoff disease, neurofibromatosis type II, Beard-Smith syndrome Stephenson skin gyration syndrome, Mediterranean fever, Familial Benjamin syndrome, Beta-thalassemia, Bilateral acoustic neurofibromatosis (Neurofibromatosis type II), Factor V Leiden thrombosis, Bloch-Sulzberger syndrome (Incontinentia pigmenti), Bloom syndrome, X-linked sideroblastic anemia, Bonnevie-Ullrich syndrome (Turner syndrome), Bourneville disease (Tuberous sclerosis), Prion diseases, Birt-Hogg-Dube syndrome, Brittle bone disease (Osteogenesis imperfecta), Broad hallux syndrome (Rubinstein-Taybi syndrome), Bronze diabetes mellitus / Bronze cirrhosis (Hemochromatosis), Bulbospinal muscular atrophy (Kennedy's disease), Burger-Grutz syndrome (lipoprotein lipase deficiency), CGD chronic granulomatous disease, cuneiform dysplasia, biotinidase deficiency, cardiomyopathy (Noonan's syndrome), cricketing syndrome, CAVD (congenital absence of the vas deferens), Cailler cardio-facial syndrome (CBAVD), CEP (congenital erythropoietic porphyria), cystic fibrosis, congenital hypothyroidism, chondrodystrophic syndrome (achondroplasia), ossicular giant epiphyseal dysplasia, Lesch-Nyhan syndrome, galactosemia, Ehlers-Danlos syndrome, lethal osteodysplasia, Coffin-Lowry syndrome,Cockayne syndrome (familial adenomatous polyposis), congenital erythropoietic porphyria, congenital heart disease, methemoglobinemia / congenital methemoglobinemia, achondroplasia, X-linked sideroblastic anemia, connective tissue disease, conotruncal dysfacies syndrome, Cooley anemia (β-thalassemia), copper storage disease (Wilson's disease), copper transport disease (Menkes disease), hereditary coproporphyria, Cowden syndrome, craniofacial dysplasia (Courzon syndrome), Creutzfeldt-Jakob disease (prion disease), Cockayne syndrome, Cowden syndrome, Curschmann-Batten-Steinert syndrome (myotonic dystrophy), Bear-Stevenson cutaneous rotation syndrome, primary hyperoxaluria, spondyloepiphyseal dysplasia (Strudwick type), degenerative neurological disorders including Duchenne and Becker muscular dystrophy (DBMD), Usher syndrome, de Grouchy syndrome and Degerines-Sottas syndrome, developmental disorders, distal spinal muscular atrophy type V, androgen insensitivity syndrome, diffuse globular sclerosis (Krabbe disease), DiGeorge syndrome, dihydrotestosterone receptor deficiency, androgen insensitivity syndrome, Down syndrome, dwarfism, erythropoietic protoporphyria erythroid 5-aminolevulinic acid synthase deficiency, erythropoietin porphyria, erythropoietin protoporphyria, erythropoietin uroporphyria, Friedreich's ataxia, familial paroxysmal polyserositis, porphyria cutanea tarda, familial pressure-sensitive neuropathy, primary pulmonary hypertension (PPH), fibrocystic disease of the pancreas, fragile X syndrome, galactosemia, hereditary encephalopathy, giant cell hepatitis (neonatal hemochromatosis), Grönblatt-Strandberg syndrome (pseudoxanthoma elasticum), Günther's disease (congenital erythropoietin porphyria), hemochromatosis, Harg Renn's syndrome, sickle cell anemia, hemophilia, myelohepatic porphyria (HEP), Hippel-Lindau disease (von Hippel-Lindau disease), Huntington's disease, Hutchinson-Gilford progeria syndrome (progeria), hyperandrogenism, hypochondroplasia, hypochromic anemia, immune system disorders including X-linked severe combined immunodeficiency, Insley-Astley syndrome, Jackson-Weiss syndrome, Joubert syndrome, Lesch-Nyhan syndrome, Jackson-Weiss syndrome, kidney disorders including hyperoxaluria, Klinefelter syndrome, Kniest dysplasia, lacunar dementia,Metabolic disorders including Langer-Sardino achondroplasia, ataxia telangiectasia, Lynch syndrome, lysyl hydroxylase deficiency, Machado-Joseph disease, Kniest dysplasia, Marfan syndrome, movement disorders, Mowat-Wilson syndrome, cystic fibrosis, Münke syndrome, multiple neurofibromatosis, Nance-Insley syndrome, Nance-Sweeney chondrodysplasia, Niemann-Pick disease, Noack syndrome (Pfeiffer syndrome), Osler-Weber-Rendu disease, Peutz-Jeghers syndrome, polycystic kidney disease, multiple fibrous dysplasia (McEune-Ollens syndrome) Bright's syndrome), Peutz-Jeghers syndrome, Prader-Lavert-Willi syndrome, hemochromatosis, primary hyperuricemia syndrome (Lesch-Nyhan syndrome), primary pulmonary hypertension, primary senile degenerative dementia, prion disease, progeria (Hutchinson-Gilford progeria syndrome), progressive chorea, chronic hereditary (Huntington's disease), progressive muscular atrophy, spinal muscular atrophy, propionic acidemia, protoporphyria, proximal myotonic dystrophy, pulmonary arterial hypertension, PXE (pseudoxanthoma elasticum), Rb (retinoblastoma), Le Neurofibromatosis type I, Recurrent polyserositis, Retinopathy, Retinoblastoma, Rett syndrome, REALS type 3, Ricker syndrome, Riley-Day syndrome, Russy-Levy syndrome, Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Li-Fraumeni syndrome, Sarcoma-Breast-Leukemia-Adrenal (SBLA) syndrome, Sclerosis tuberous (tuberous sclerosis), SDAT, SED (spondyloepiphyseal dysplasia congenita), SED Strudwick (spondyloepiphyseal dysplasia, Strudwick type), SEDc (spondyloepiphyseal dysplasia congenita)S EMD, Strudwick type (spondyloepiphyseal dysplasia, Strudwick type), Shprintzen syndrome, dyschromia, Smith-Lemli-Opitz syndrome, South African hereditary porphyria (variegate porphyria), infantile-onset ascending spastic paralysis, speech and communication disorder, sphingolipidosis, Tay-Sachs disease, spinocerebellar ataxia, Stickler syndrome, stroke, androgen insensitivity syndrome, tetrahydrobiopterin deficiency, beta-thalassemia, thyroid disease, sausage neuropathy (hereditary neuropathy with pressure palsies),These include Treacher Collins syndrome, Triplo X syndrome (Triple X syndrome), Trisomy 21 (Down syndrome), Trisomy X, VHL syndrome (von Hippel-Lindau disease), Visual impairment and blindness (Alström syndrome), Vrolic disease, Waardenburg syndrome, Warburg-Schör-Fredelius syndrome, Weissenbacher-Zweimüller syndrome, Wolf-Hirschorn syndrome, Wolff periodic disorder, Weissenbacher-Zweimüller syndrome, and xeroderma pigmentosum.
[0146] Combination therapy The ARRDC1 fusion proteins or ARMM disclosed herein can be used alone or in combination in effective amounts to treat a subject having a disorder described herein.
[0147] The ARRDC1 fusion protein or ARMM disclosed herein can be used in an effective amount alone or in combination with another ARRDC1 fusion protein or ARMM disclosed herein or another bioactive agent to treat a subject having a disorder described herein.
[0148] In some embodiments, the ARRDC1 fusion protein or ARMM of the present disclosure and the bioactive agent are administered to be active in vivo during overlapping time periods, for example, to have overlapping Cmax, Tmax, AUC or other pharmacokinetic parameters. In some embodiments, the ARRDC1 fusion protein or ARMM of the present disclosure and the bioactive agent are administered to a host in need thereof, but they do not have overlapping pharmacokinetic parameters, however, one has a therapeutic effect on the therapeutic effect of the other.
[0149] In some embodiments, the bioactive agent is an immune modulator, including but not limited to, checkpoint inhibitors, including, by way of non-limiting examples, PD-1 inhibitors, PD-L1 inhibitors, PD-L2 inhibitors, CTLA-4 inhibitors, LAG-3 inhibitors, TIM-3 inhibitors, V-domain Ig suppressor of T-cell activation (VISTA) inhibitors, small molecules, peptides, nucleotides, or other inhibitors. In certain aspects, the immune modulator is an antibody, such as a monoclonal antibody.
[0150] PD-1 inhibitors, which bind to the PD-1 receptor to block the interaction between PD-1 and PD-L1 and inhibit immunosuppression, include, for example, nivolumab (Opdivo), pembrolizumab (Keytruda), pidilizumab, AMP-224 (AstraZeneca and MedImmune), PF-06801591 (Pfizer), MEDI0680 (AstraZeneca), spartalizumab (Novartis), REGN2810 (Regeneron), SHR-12-1 (Jiangsu Hengrui Medicine Company and Incyte Corporation). These include PD-L1 inhibitors, which bind to the PD-L1 receptor, thereby blocking the interaction between PD-1 and PD-L1, and inhibit immunosuppression, such as atezolizumab (Tecentriq), durvalumab (AstraZeneca and MedImmune), KN035 (Alphamab), and BMS-936559 (Bristol-Myers Squibb). CTLA-4 checkpoint inhibitors, which bind to CTLA-4, inhibit immunosuppression, include, but are not limited to, ipilimumab, tremelimumab (AstraZeneca and MedImmune), AGEN1884, and AGEN2041 (Agenus). LAG-3 checkpoint inhibitors include, but are not limited to, BMS-986016 (Bristol-Myers Squibb), GSK2831781 (GlaxoSmithKline), IMP321 (Prima BioMed), LAG525 (Novartis), and the dual PD-1 and LAG-3 inhibitor MGD013 (MacroGenics).Examples of TIM-3 inhibitors include sabatolimab (Novartis) and TSR-022 (Tesaro).
[0151] In some embodiments, the bioactive agent is an ALK inhibitor. Examples of ALK inhibitors include, but are not limited to, crizotinib, alectinib, ceritinib, TAE684 (NVP-TAE684), GSK1838705A, AZD3463, ASP3026, PF-06463922, entrectinib (RXDX-101), and AP26113.
[0152] In some embodiments, the bioactive agent is an EGFR inhibitor. Examples of EGFR inhibitors include erlotinib (Tarceva), gefitinib (Iressa), afatinib (Gilotrif), rociletinib (CO-1686), osimertinib (Tagrisso), olmutinib (Olita), nactinib (ASP8273), nazartinib (EGF816), PF-06747775 (Pfizer), icotinib (BPI-2009), neratinib (HKI-272; PB272); avitinib (AC0010), EAI045, tarloxotinib (TH-4000; PR-610), PF-06459988 (Pfizer), tesevatinib (XL647; EXEL-7647; KD-019), transtinib, WZ-3146, WZ8040, CNX-2006, and dacomitinib (PF-00299804; Pfizer).
[0153] In some embodiments, the bioactive agent is a HER-2 inhibitor. Examples of HER-2 inhibitors include trastuzumab, lapatinib, adotrastuzumab emtansine, and pertuzumab. In some embodiments, the bioactive agent is a CD20 inhibitor. Examples of CD20 inhibitors include obinutuzumab, rituximab, fatumumab, ibritumomab, tositumomab, and ocrelizumab. In some embodiments, the bioactive agent is a JAK3 inhibitor. Examples of JAK3 inhibitors include tasocitinib.
[0154] In one embodiment, the bioactive agent is a BCL-2 inhibitor. Examples of BCL-2 inhibitors include venetoclax, ABT-199 (4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide), ABT-737 (4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl), and venetoclax (4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl). navitoclax), ABT-263 ((R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3((trifluoromethyl) )sulfonyl)phenyl)sulfonyl)benzamide), GX15-070 (Obatoclax mesylate, (2Z)-2-[(5Z)-5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole; methanesulfonic acid))), 2-Methoxyantimycin A3, YC137 (4-(4,9-dioxo-4,9-dihydronaphtho[2,3-d]thiazol-2-ylamino)phenyl ester), Pogosine, Ethyl 2-amino-6-bromo -4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate, nilotinib-d3, TW-37 (N-[4-[[2-(1,1-dimethylethyl)phenyl]sulfonyl]phenyl]-2,3,4-trihydroxy-5-[[2-(1-methylethyl)phenyl]methyl]benzamide), apogossypolone (ApoG2), HA14-1, AT101, sabutoclax, gambogic acid, or G3139 (Oblimersen).
[0155] In some embodiments, the bioactive agent is a kinase inhibitor. In some embodiments, the kinase inhibitor is selected from a phosphoinositide 3-kinase (PI3K) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, or a spleen tyrosine kinase (Syk) inhibitor, or a combination thereof.
[0156] Examples of PI3 kinase inhibitors include, but are not limited to, wortmannin, demethoxyviridin, perifosine, idelalisib, pictilisib, paromid 529, ZSTK474, PWT33597, CUDC-907, and AEZS-136, duvelisib, GS-9820, BKM120, GDC-0032 (taselisib) (2-[4-[2-(2-isopropyl-5-methyl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl ]-2-methylpropanamide), MLN-1117 ((2R)-1-phenoxy-2-butanyl hydrogen (S)-methylphosphonate; or methyl(oxo){[(2R)-1-phenoxy-2-butanyl]oxy}phosphonium), BYL-719 ((2S)-N1-[4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide), GSK2126458 (2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridyl) quinolinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide) (omipalisib), TGX-221 ((+)-7-methyl-2-(morpholin-4-yl)-9-(1-phenylaminoethyl)-pyrido[1,2-a]-pyrimidin-4-one), GSK2636771 (2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid dihydrochloride), KIN-193 ((R)-2-((1-(7-methyl-2-morpholino-4-oxo-4H-pyrido [1,2-a]pyrimidin-9-yl)ethyl)amino)benzoic acid), TGR-1202 / RP5264, GS-9820 ((S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-mohydroxypropan-1-one), GS-1101 (5-fluoro-3-phenyl-2-([S]-1-[9H-purin-6-ylamino]-propyl)-3H-quinazolin-4-one), AMG-319, GSK-2269557, SAR245409 (N-(4-(N-(3-((3,5-dimethoxyphenyl)amino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-methoxy-4-methylbenzamide), BAY80-6946 (2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo[1,2-c]quinaz), AS 252424 (5-[1-[5-(4-fluoro-2-hydroxy-phenyl)-furan-2-yl]-meth-(Z)-ylidene]-thiazolidine-2,4-dione), CZ 24832 (5-(2-amino-8-fluoro-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-tert-butylpyridine-3-sulfonamide), buparlisib (5-[2,6-di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine), GDC-0941 (2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl) 1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one (also known as RG7422)), SF1126 ((8S,14S,17S)-14-(calcium)-1,3-dihydropyrimidin-4-yl), ... POLYMETHYL)-8-(3-GUANIDINOPROPYL)-17-(HYDROXYMETHYL)-3,6,9,12,15-PENTAOXO-1-(4-(4-OXO-8-PHENYL-4H-CHROMEN-2-YL)MORPHOLINO-4-IUM)-2-OXA-7,10,13,16-TETRAAZAOCTADECANE-18-OATE), PF-05212384 (N-[4-[[4-(DIMETHYLAMINO)-1-PIPERIDINYL]CARBONYL]PHENYL) ]-N'-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]urea) (gedatricisib), LY3023414, BEZ235 (2-methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile) (dactolisib), XL-765 (N-(3-(N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-methoxy-4-methylbenzamide), and GSK1059615 (5-[[4-(4-pyridinyl)-6-quinolinyl]methylene]-2,4-thiazolidinedione), PX886 ([(3aR,6E,9S,9aR,10R,11aS)-6-[[bis(prop-2-enyl)amino]methylidene]-5-hydro 9-(methoxymethyl)-9a,11a-dimethyl-1,4,7-trioxo-2,3,3a,9,10,11-hexahydroindeno[4,5h]isochromen-10-yl]acetate (also known as sonolisib), LY294002, AZD8186, PF-4989216, pyraralisib, GNE-317, PI-3065, PI-103, NU7441 (KU-57788), HS 173, VS-5584 (SB2343), CZC24832, TG100-115, A66, YM201636, CAY10505, PIK-75, PIK-93, AS-605240, BGT226 (NVP-BGT226), AZD6482, voxtalisib, alpelisib, IC-87114, TGI100713, CH5132799, PKI-402, copanlisib (BAY 80-6946), XL 147, PIK-90, PIK-293, PIK-294, 3-MA (3-methyladenine), AS-252424, AS-604850, apitolisib (GDC-0980; RG7422).
[0157] Examples of BTK inhibitors include ibrutinib (also known as PCI-32765) (Imbruvica™) (1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one), dianilinopyrimidine inhibitors such as AVL-101 and AVL-291 / 292 (N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide) (Avila Therapeutics, Inc., New Jersey, USA) Therapeutics) (see U.S. Patent Application Publication No. 2011 / 0117073, incorporated herein in its entirety), dasatinib ([N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide], LFM-A13 (α-cyano-β-hydro β-methyl-N-(2,5-dibromophenyl)propenamide), GDC-0834 ([RN-(3-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide], CGI-560 4-(tert-butyl)-N-(3-(8-(phenylamino)imidazo[1,2-a]pyrazin-6-yl)phenyl)benzamide, CGI-1746 (4-(tert-butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide), CNX-774 (4-(4- ((4-((3-acrylamidophenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenoxy)-N-methylpicolinamide), CTA056 (7-benzyl-1-(3-(piperidin-1-yl)propyl)-2-(4-(pyridin-4-yl)phenyl)-1H-imidazo[4,5-g]quinoxalin-6(5H)-one), GDC-0834 ((R)-N-(3-(6-((4-(1,4-Dimethyl-3-oxopiperazin-2-yl)phenyl)amino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide), GDC-0837 ((R)-N-(3-(6-((4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenyl)amino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide), (4-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide), HM-71224, ACP-196, ONO-4059 (Ono Pharmaceutical Co., Ltd.), PRT062607 (4-((3-(2H-1,2,3-triazol-2-yl)phenyl) and other molecules capable of inhibiting BTK activity, such as Akinleye's 1-(1-acryloylindolin-6-yl)-9-(1-methyl-1H-pyrazol-4-yl)benzo[h][1,6]naphthyridin-2(1H)-one), QL-47 (1-(1-acryloylindolin-6-yl)-9-(1-methyl-1H-pyrazol-4-yl)benzo[h][1,6]naphthyridin-2(1H)-one), and RN486 (6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one), which are incorporated herein by reference in their entirety. et al., Journal of Hematology & Oncology, 2013, 6:59.
[0158] Syk inhibitors include, for example, celduratinib (4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide), entospletinib (6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine), fostamatinib ([6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pi rimidinyl}amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate), fostamatinib disodium salt (Sodium (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate), BAY 61-3606 (2-(7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino)-nicotinamide HCl), RO9021 (6-[(1R,2S)-2-amino-cyclohexylamino]-4-(5,6-dimethyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide), Imatinib (Gleevac; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide), Staurosporine, GSK143 (2-(((3R,4R)-3-aminotetrahydrofuran) Hydro-2H-pyran-4-yl)amino)-4-(p-tolylamino)pyrimidine-5-carboxamide), PP2 (1-(tert-butyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine), PRT-060318 (2-(((1R,2S)-2-aminocyclohexyl)amino)-4-(m-tolylamino)pyrimidine-5-carboxamide), PRT-062607 (4-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-2-(((1R,2S)-2-aminocyclohexyl)amino)pyrimidine-5-carboxamide hydrochloride), R112 (3,3'-((5-fluoropyrimidine-2,4-diyl)bis(azanediyl))diphenol), R348 (3-ethyl-4-methylpyridine), R406 (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one), piceatannol (3-hydroxyresveratrol), YM193306 (see Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643), 7-azaindole, piceatannol, ER-27319 (see Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643, which is incorporated herein in its entirety). Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643), Compound D (see, Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643, which is incorporated herein in its entirety), PRT060318 (see, Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643, which is incorporated herein in its entirety), luteolin (see, Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643, which is incorporated herein in its entirety). 2012, 55,3614-3643), apigenin (see, Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643, which is incorporated herein in its entirety), quercetin (see, Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643, which is incorporated herein in its entirety), fisetin (see, Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643, which is incorporated herein in its entirety), myricetin (see, Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643, which is incorporated herein in its entirety). Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643), and morin (see Singh et al. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors, J. Med. Chem. 2012, 55, 3614-3643, which is incorporated herein in its entirety).
[0159] In some embodiments, the bioactive agent is a MEK inhibitor. MEK inhibitors are well known and include, for example, trametinib / GSK1120212 (N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H-yl}phenyl)acetamide), selumetinib (6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide), pimasertib / AS703026 / MSC 1935369 ((S)-N-(2,3-dihydroxypropyl)-3-((2-fluoro-4-iodophenyl)amino)isonicotinamide), XL-518 / GDC-0973 (1-({3,4-dichloro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S)-piperidin-2-yl]azetidin-3-ol), refametinib / BAY869766 / RDEA1 19 (N-(3,4-dichloro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide), PD-0325901 (N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide), TAK733 ((R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione), ME K162 / ARRY438162 (5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide), R05126766 (3-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]methyl]-4-methyl-7-pyrimidin-2-yloxychromen-2-one), WX-554, R04987655 / CH4987655 (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-5-((3-oxo-1,2-oxazinan-2yl)methyl)benzamide), or AZD8330 (2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide), U0126-EtOH, PD 184352 (CI-1040), GDC-0623, BI-847325, cobimetinib, PD98059, BIX 02189, BIX 02188, binimetinib, SL-327, TAK-733, PD318088.
[0160] In some embodiments, the bioactive agent is a Raf inhibitor. Raf inhibitors are known, for example, vemurafinib (N-[3-[[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide), sorafenib tosylate (4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-Methylbenzenesulfonate), AZ628 (3-(2-cyanopropan-2-yl)-N-(4-methyl-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)benzamide), NVP-BHG712 (4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)phenyl)benzamide). (phenyl)benzamide), RAF-265 (1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine), 2-bromoardisine (2-bromo-6,7-dihydro-1H,5H-pyrrolo[2,3-c]azepine-4,8-dione), Raf kinase inhibitor IV (2-chloro -5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol), sorafenib N-oxide (4-[4-[[[[4-chloro-3(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide 1-oxide), PLX-4720, dabrafenib (GSK2118436), GDC-0879, RAF265, AZ 628, SB590885, ZM336372, GW5074, TAK-632, CEP-32496, LY3009120, and GX818 (encorafenib).
[0161] In some embodiments, the bioactive agent is an AKT inhibitor, including but not limited to, MK-2206, GSK690693, perifosine, (KRX-0401), GDC-0068, triciribine, AZD5363, honokiol, PF-04691502, and miltefosine, an FLT-3 inhibitor, including but not limited to, P406, dovitinib, quizartinib (AC220), amuvatinib (MP-470), tandutinib (MLN518), ENMD-2076, and KW-2449, or a combination thereof.
[0162] In some embodiments, the bioactive agent is an mTOR inhibitor. Examples of mTOR inhibitors include, but are not limited to, rapamycin and its analogs, everolimus (Ahumitol), temsirolimus, ridaforolimus, sirolimus, and deforolimus. Examples of MEK inhibitors include, but are not limited to, tametinib / GSK1120212 (N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H-yl}phenyl)acetamide), selmetinob (6-(4-bromo-2-chlorophenyl)pyrimidin-1(2H-yl) ... anilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide), pimasertib / AS703026 / MSC1935369 ((S)-N-(2,3-dihydroxypropyl)-3-((2-fluoro-4-iodophenyl)amino)isonicotinamide), XL-518 / GDC-0973 (1-({3,4-difluoro-2-[(2 -fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S)-piperidin-2-yl]azetidin-3-ol) (cobimetinib), refametinib / BAY869766 / RDEA119 (N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonyl) sulfonamide), PD-0325901 (N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide), TAK733 ((R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3d]pyrimidine-4,7(3H,8H)-dione), MEK162 / ARRY438162 (5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide), R05126766 (3-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]methyl]-4-methyl-7-pyrimidin-2-yloxychromen-2-one), WX-554, R0498 7655 / CH4987655 (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-5-((3-oxo-1,2-oxazinan-2-yl)methyl)benzamide), or AZD8330 (2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide).
[0163] In some embodiments, the bioactive agent is a RAS inhibitor. Examples of RAS inhibitors include, but are not limited to, Reolysin and siG12D LODER. In some embodiments, the bioactive agent is an HSP inhibitor. HSP inhibitors include, but are not limited to, geldanamycin or 17-N-allylamino-17-demethoxygeldanamycin (17AAG), and radicicol.
[0164] Further biologically active compounds include, for example, everolimus, trabectedin, abraxane, TLK286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, FLT-3 inhibitors, VEGFR inhibitors, Aurora kinase inhibitors, PIK-1 modulators, HDAC inhibitors, c-MET inhibitors, PARP inhibitors, Cdk inhibitors, IGFR-TK inhibitors, anti-HGF antibodies, focal adhesion kinase inhibitors, inhibitor), MAP kinase kinase (mek) inhibitor, VEGF trap antibody, pemetrexed, panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, azd2171, butabulin, ofatumumab, zanolimumab, edotecarin, tetrandrine, rubitecan, tesmilifene, oblimersen, ticilimumab, ipilimumab, gossypol, Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC 8490, cilengitide, gimatecan, IL13-PE38QQR, INO 1001, IPdRiKRX-0402, lucanton, LY317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, doxorubicin, liposomal doxorubicin, 5'-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709, seliciclib; PD0325901, AZD-6244, capecitabine, L-glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolidinyl)-2-(4-oxo-1H-pyrrolidinyl)-2-(2-amino-4,7-dihydro- ... 2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt, heptahydrate, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrazole, exemestane, letrozole, DES (diethylstilbestrol), estradiol, estrogen, conjugated estrogens, bevacizumab, IMC-1C11, CHIR-258; 3-[5-(methylsulfonylpiperazine methyl) -Indolylquinolones, Vatalanib, AG-013736, AVE-0005, Goserelin acetate, Leuprolide acetate, Triptorelin pamoate, Medroxyprogesterone acetate, Hydroxyprogesterone caproate, Megestrol acetate, Raloxifene, Bicalutamide, Flutamide, Nilutamide, Megestrol acetate, CP-724714; TAK-165, HKI-272, Erlotinib, Lapatanib, Canertinib, ABX- EGF antibody, Erbitux, EKB-569, PKI-166, GW-572016, lonafarnib, BMS-214662, tipifarnib; amifostine, NVP-LAQ824, suberoylanalide hydroxamic acid, valproic acid, trichostatin A, FK-228, SU111248, sorafenib, KRN951, aminoglutethimide, amsacrine, anagrelide, L-asparaginase, Bacillus Calmette-GuerinCalmette-Guerin (BCG) vaccine, adriamycin, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, Gleevec, gemcitabine, hydroxyurea, idarubicin, ifosfamide, imatinib, leuprolide ... Mizole, lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard, uracil mustard, estrastatin, Mustine, altretamine, floxuridine, 5-deoxyuridine, cytosine arabinoside, 6-mercaptopurine, deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine, vinorelbine, topotecan, razoxine, marimastat, COL-3, neovastat, BMS-275291, squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin-12, IM862, angiostatin, vitaxin, droloxifene, idoxifene, spironora , finasteride, cimitidine, trastuzumab, denileukin diftitox, gefitinib, bortezimib, paclitaxel, paclitaxel without cremophor, docetaxel, epithilone B, BMS-247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene, fulvestrant, acolbifene, lasofoxifene, idoxifene, TSE-424, HMR-3339, ZK186619, topotecan, PTK787 / ZK 222584, VX-745, PD184352, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zoledronate, Prednisone, cetuximab, granulocyte-macrophage colony-stimulating factor, histrelin, pegylated interferon alfa-2a, interferon alfa-2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab, all-trans retinoic acid, ketoconazole , interleukin-2, megestrol, immunoglobulin, nitrogen mustard, methylprednisolone, ibritumomab tiuxetan, androgens, decitabine, hexamethylmelamine, bexarotene, tositumomab, arsenic trioxide, cortisone, etidronate, mitotane, cyclosporine, liposomal daunorubicin, edwina asparaginase, strontium-89, casopitant, netupitant, NK-1 receptor antagonist , palonosetron, aprepitant, diphenhydramine, hydroxyzine, metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methylprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfidograstim, erythropoietin, epoetin alfa, darbepoetin alfa, and mixtures thereof.
[0165] In some embodiments, the bioactive agent is an agent such as, but not limited to, imatinib mesylate (Gleevec®), dasatinib (Sprycel®), nilotinib (Tasigna®), bosutinib (Boslif®), trastuzumab (Herceptin®), trastuzumab-DM1, pertuzumab (Perjeta™), lapatinib (Tykerb®), gefitinib (Iressa®), erlotinib (Tarceva®), cetuximab (Erbitux®), panitumumab (Vectibix®), vandetanib (Caprelsa®), vemurafenib (Zelboraf®), Selected from vorinostat (Zolinza®), romidepsin (Istodax®), bexarotene (Tagretin®), alitretinoin (Panretin®), tretinoin (Vesanoid®), carfilizomib (Kyprolis™), pralatrexate (Folotin®), bevacizumab (Avastin®), diabflibercept (Zaltrap®), sorafenib (Nexavar®), sunitinib (Sutent®), pazopanib (Votrient®), regorafenib (Stivarga®), and cabozantinib (Cometriq™).
[0166] In some aspects, the bioactive agent is an anti-inflammatory agent, a chemotherapeutic agent, a radiotherapeutic agent, an additional therapeutic agent, or an immunosuppressant agent.
[0167] Suitable chemotherapeutic bioactive agents include, but are not limited to, radioactive molecules, toxins, also called cytotoxins or cytotoxic agents, including any agent detrimental to cell viability, and liposomes or other vesicles containing chemotherapeutic compounds. Common anti-cancer drugs include vincristine (Oncovin®) or liposomal vincristine (Marquivo®), daunorubicin (Daunomycin or Cervizin®) or doxorubicin (Adriamycin®), cytarabine (cytosine arabinoside, ara-C, or Cytosar®), L-asparaginase (Elspar®) or PEG-L-asparaginase (pegaspargase or Oncaspar®), These include rituximab (registered trademark), etoposide (VP-16), teniposide (Bumon®), 6-mercaptopurine (6-MP or Purinetol®), methotrexate, cyclophosphamide (Cytoxan®), prednisone, dexamethasone (Decadron), imatinib (Gleevec®), dasatinib (Sprycel®), nilotinib (Tasigna®), bosutinib (Boslif®), and ponatinib (Iclusig™). Examples of additional suitable chemotherapeutic agents include, but are not limited to, 1-dehydrotestosterone, 5-fluorouracil decarbazine, 6-mercaptopurine, 6-thioguanine, actinomycin D, adriamycin, aldesleukin, alkylating agents, allopurinol sodium, altretamine, amifostine, anastrozole, anthramycin (AMC), antimitotic agents, cis-dichlorodiamineplatinum(II) (DDP), cisplatin, diaminodichloroplatinum, anthracyclines, antibiotics, Substances, Antimetabolites, Asparaginase, Live BCG (intravesical), Betamethasone Sodium Phosphate and Betamethasone Acetate, Bicalutamide, Bleomycin Sulfate, Busulfan, Leucovorin Calcium, Calicheamicin, Capecitabine, Carboplatin, Lomustine (CCNU), Carmustine (BSNU), Chlorambucil, Cisplatin, Cladribine, Colchicine, Conjugated Estrogens, Cyclophosphamide, Cyclothosphamide, Cytarabine,Cytochalasin B, Cytoxan, Dacarbazine, Dactinomycin, Dactinomycin (formerly Actinomycin), Daunirubicin HCL, Daunorubicin Citrate, Denileukin Diftitox, Dexrazoxane, Dibromomannitol, Dihydroxyanthracin dione, Docetaxel, Dolasetron Mesylate, Doxorubicin HCL, Dronabinol, E. coli L-Asparaginase, Emetine, Epoetin-α, Erwinia L-Asparaginase, Esterified Estrogens , estradiol, estramustine sodium phosphate, ethidium bromide, ethinyl estradiol, etidronate, etoposide citrovorum factor, etoposide phosphate, filgrastim, floxuridine, fluconazole, fludarabine phosphate, fluorouracil, flutamide, folic acid, gemcitabine HCL, glucocorticoids, goserelin acetate, gramicidin D, granisetron HCL, hydroxyurea, idarubicin HCL, ifosfamide, interferon alpha-2b, irinotecan HCL, letrozole, Leucovorin calcium, leuprolide acetate, levamisole HCL, lidocaine, lomustine, maytansinoids, mechlorethamine HCL, medroxyprogesterone acetate, megestrol acetate, melphalan HCL, mercaptiprine, mesna, methotrexate, methyltestosterone, mithramycin, mitomycin C, mitotane, mitoxantrone, nilutamide, octreotide acetate, ondansetron HCL, paclitaxel, pamidronate disodium, pentostatin, pilocarpine HCL, primycin , Polypheprosan 20 with Carmustine Implant, Porfimer Sodium, Procaine, Procarbazine HCL, Propranolol, Rituximab, Sargramostim, Streptozotocin, Tamoxifen, Taxol, Teniposide, Tenoposide, Testolactone, Tetracaine, Thioepachlorambucil, Thioguanine, Thiotepa, Topotecan HCL, Toremifene Citrate, Trastuzumab, Tretinoin, Valrubicin, Vinblastine Sulfate, Vincristine Sulfate, and Vinorelbine Tartrate.
[0168] Additional therapeutic agents that may be administered in combination with the degronimers disclosed herein include bevacizumab, sutanib, sorafenib, 2-methoxyestradiol or 2ME2, finasunate, vatalanib, vandetanib, aflibercept, volociximab, etaracizumab (MEDI-522), cilengitide, erlotinib, cetuximab, panitinib, and the like. tumumab, gefitinib, trastuzumab, dovitinib, figitumumab, atacicept, rituximab, alemtuzumab, aldesleukin, atlizumab, tocilizumab, temsirolimus, everolimus, lucatumumab, dacetuzumab, HLL1, huN901-DM1, atiprimod, natalizumab, bortezomib, carfilzomib, marizomib, tanespimycin, saquinavir mesylate, ritonavir, nephropathy, rheumatoid arthritis ... Rufinavir mesylate, indinavir sulfate, belinstat, panobinostat, mapatumumab, lexatumumab, dulanermin, ABT-737, oblimersen, plitidepsin, talmapimod, P276-00, enzastaurin, tipifarnib, perifosine, imatinib, dasatinib, lenalidomide, thalidomide, simvastatin, celecoxib, bazedoxifene, AZD4547, rilotinib These may include ramucirumab, oxaliplatin (Eloxatin), PD0332991, ribociclib (LEE011), amevaciclib (LY2835219), HDM201, fulvestrant (Faslodex), exemestane (Aromasin), PIM447, ruxolitinib (INC424), BGJ398, necitumumab, pemetrexed (Alimta), and ramucirumab (IMC-1121B).
[0169] In some aspects, the ARRDC1 fusion protein or ARMM disclosed herein is administered in combination with an anti-infective agent, such as, but not limited to, an anti-HIV agent, an anti-HCV agent, an anti-HBV agent, or other anti-viral or antibacterial agent. In one embodiment, the anti-HIV agent can be, but is not limited to, a nucleoside reverse transcriptase inhibitor (NRTI), other non-nucleoside reverse transcriptase inhibitor, a protease inhibitor, a fusion inhibitor, etc. Nucleoside / nucleotide reverse transcriptase inhibitors (NRTI) include, but are not limited to, abacavir or ABC (Ziagen), didanosine or ddl (Videx), emtricitabine or FTC (Emtriva), lamivudine or 3TC (Epivir), ddC (Zalcitabine), stavudine or d4T (Zerrit), tenofovircol TDF (Viread), D-D4FC (Reverset), and zidovudine or AZT or ZDV (Retrovir). Non-nucleoside reverse transcriptase inhibitors (NNRTIs) include, but are not limited to, delavirdine (Rescriptor), efavirenz (Sustiva), etravirine (Intelence), nevirapine (Viramune), and rilpivirine (Edurant). Anti-HIV protease inhibitors (PIs) include, but are not limited to, atazanavir or ATV (Reyataz), darunavir or DRV (Prezias), fosamprenavir or FPV (Rexiva), indinavir or IDV (Crixivan), lopinavir + ritonavir or LPV / r (Kaletra), nelfinavir or NFV (Viracept), ritonavir or RTV (Norvir), saquinavir or SQV (Invirase), tipranavir or TPV (Aptivas), cobicistat (Tyvost), atazanavir + cobicistat or ATV / COBI (Evotaz), darunavir + cobicistat or DRV / COBI (Prescovix). Anti-HIV fusion inhibitors include, but are not limited to, enfuvirtide, or ENF, or T-20 (Fuseon). Anti-HIV agents also include, but are not limited to, maraviroc or MVC (Clsentry).Anti-HIV integrase inhibitors include, but are not limited to, dolutegravir (Tevikai), elvitegravir (Vitekta), and raltegravir (Isentress). Anti-HIV combination drugs include abacavir + dolutegravir + lamivudine, or ABC / DTG / 3TC (Trimeq), abacavir + lamivudine, or ABC / 3TC (Epzicom), abacavir + lamivudine + zidovudine, or ABC / 3TC / ZDV (Trizivir), efavirenz + emtricitabine + tenofovir, or EFV / FTC / TDF (Atripla, Tribuss), elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide, or EVG / CO. These include BI / FTC / TAF or ECF / TAF (Genvoya; (Stribild)), emtricitabine + rilpivirine + tenofovir or FTC / RPV / TAF (Odefcy); emtricitabine + rilpivirine + tenofovir or FTC / RPV / TDF (Complera), emtricitabine + tenofovir or TAF / FTC (Descovy), emtricitabine and tenofovir disoproxil fumarate (Truvada), and lamivudine + zidovudine or 3TC / ZDV (Combivir). Other anti-HIV compounds include, but are not limited to, fusion inhibitors such as rasvir, L-FddC, L-FD4C, SQVM (saquinavir mesylate), IDV (indinavir), SQV (saquinavir), APV (amprenavir), LPV (lopinavir), T20, and fusions and mixtures thereof, including anti-HIV compounds currently in clinical trials or development.
[0170] Other anti-HIV agents that may be used in co-administration with the ARRDC1 fusion proteins or ARMM disclosed herein include nevirapine (BI-R6-587), delavirdine (U-90152S / T), efavirenz (DMP-266), UC-781 (N-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3-furancarbotiamide), etravirine (TMC 125), trovirdine (Ly300046.HCl), HI-236, HI-240, HI-280, HI-281, rilpivirine (TMC-278), MSC-127, HBY 097, DMP266, Baicalin (TJN-151) ADAM-II (methyl 3',3'-dichloro-4',4"-dimethoxy-5',5"-bis(methoxycarbonyl)-6,6-Diphenylhexenoate), Methyl 3-bromo-5-(1-5-bromo-4-methoxy-3-(methoxycarbonyl)phenyl)hept-1-enyl)-2-methoxybenzoate (alkenyl diarylmethane analog, Adam analog), (5-chloro-3-(phenylsulfinyl)-2'-indolecarboxamide), AAP-BHAP (U-104489 or PNU-104489), Capravirine (AG-1549, S-1153), Atevirdine (U-87201E), Aurintricarboxylic acid (SD-095345), 1-[(6-cyano-2-indolyl)carbonyl]-4-[3-(isopropylamino)-2-pi lysinyl]piperazine, 1-[5-[[N-(methyl)methylsulfonylamino]-2-indolylcarbonyl-4-[3-(isopropylamino)-2-pyridinyl]piperazine, 1-[3-(ethylamino)-2-[pyridinyl]-4-[(5-hydroxy-2-indolyl)carbonyl]piperazine, 1-[(6-formyl-2-indolyl)carbonyl]-4-[3-(isopropylamino)-2-pyridinyl]piperazine, 1-[[5-(methylsulfonyloxy)-2-indolyl)carbonyl]-4-[3-(isopropylamino)-2-pyridinyl]piperazine, U88204E, bis(2-nitrophenyl)sulfone (NSC 633001), calanolide A (NSC675451), calanolide B, 6-benzyl-5-methyl-2-(cyclohexyloxy)pyrimidin-4-one (DABO-546), DPC 961, E-EBU, E-EBU-dm, E-EPSeU, E-EPU, Foscarnet (Foscavir), HEPT (1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine), HEPT-M (1-[(2-hydroxyethoxy)methyl]-6-(3-methylphenyl)thio)thymine), HEPT-S (1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)-2-thiothymine), Inophyllum P, L-737,126, Mikellamine A (NSC650898), Mikellamine B (NSC649324), Mikellamine F, 6-(3,5-dimethylbenzyl)-1-[(2-hydroxyethoxy)methyl]-5-isopropyluracil, 6-(3,5-Dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil, NPPS, E-BPTU (NSC 648400), Oltipraz (4-methyl-5-(pyrazinyl)-3H-1,2-dithiole-3-thione), N-{2-(2-chloro-6-fluorophenethyl]-N'-(2-thiazolyl)thiourea (PETT Cl, F derivatives), N-{2-(2,6-difluorophenethyl]-N'-[2-(5-bromopyridyl)]thiourea {PETT derivatives), N-{2-(2,6-difluorophenethyl]-N'-[2-(5-methylpyridyl)thiourea {PETT pyridyl derivatives), N-[2-(3-fluorofuranyl)ethyl]-N'-[2-(5-chloropyridyl)]thiourea, N-[2-(2-fluoro-6-ethoxyphenethyl)]-N'-[2-(5-bromopyridyl)]thiourea, N-(2-phenethyl)-N'-(2-thiazolyl)thiourea (LY-73497), L-697,639, L-697,593, L-697,661, 342-(4,7-difluorobenzoxazol-2-yl)ethyl}-5-ethyl-6-methyl(pipridine-2(1H)-thione (2-pyridinone derivative), 3-[[(2-methoxy-5,6-dimethyl-3-pyridyl)methyl]amine]-5-ethyl-6-methyl(pipridine-2(1H)-thione, R82150, R82913, R87232, R88703, R89439 (Robilid), R90385, S-2720, Suramin sodium, TBZ (thiazolbenzimidazole, NSC 625487), thiazoloisoindol-5-one, (+)(R)-9b-(3,5-dimethylphenyl-2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-one, tivirapine (R86183), UC-38 and UC-84.
[0171] In other embodiments, the disclosed ARRDC1 fusion protein or ARMM, when used to treat HCV infection, can be administered in combination with another anti-HCV agent. Anti-HCV agents are known in the art. To date, many fixed-dose combinations have been approved for the treatment of HCV. Harvoni® (Gilead Sciences, Inc.) contains the NS5A inhibitor ledipasvir and the NS5B inhibitor sovosbuvir. Technivi™ (AbbVie, Inc.) is a fixed-dose combination containing the NS5A inhibitor ombitasvir, the NS3 / 4A protease inhibitor paritaprevir, and the CYP3A inhibitor ritonavir. Daklinza™ (daclatasvir, Bristol-Myers Squibb) is an HCV NS5A inhibitor indicated for use in combination with sovosbuvir to treat chronic genotype 3 infection. Zepatier™ (Merck & Co.) was recently approved for the treatment of chronic HCV genotypes 1 and 4. Zepatier™ is a fixed-dose combination product containing elbasvir, an HCV NS5A inhibitor, and grazoprevir, an HCV NS3 / 4A protease inhibitor. Zepatier™ is indicated with or without ribavirin. Epcloza® (Gilead Sciences, Inc.) is a fixed-dose combination tablet containing sovosbuvir and velpatasvir.
[0172] In some embodiments, the additional therapy is a monoclonal antibody (MAb). Some MAbs stimulate an immune response that destroys cancer cells. Similar to antibodies naturally produced by B cells, these MAbs can "coat" the surface of cancer cells and induce the immune system to destroy them. For example, bevacizumab targets vascular endothelial growth factor (VEGF), a protein secreted by tumor cells and other cells in the tumor microenvironment that promotes the development of tumor blood vessels. When bound to bevacizumab, VEGF is unable to interact with its cell receptor, preventing signaling that leads to the growth of new blood vessels.
[0173] Similarly, cetuximab and panitumumab target the epidermal growth factor receptor (EGFR), and trastuzumab targets human epidermal growth factor receptor 2 (HER-2). MAbs that bind to cell surface growth factor receptors can block the targeted receptor from sending out normal growth-promoting signals. They can also induce apoptosis and activate the immune system to destroy tumor cells.
[0174] In some embodiments, the bioactive agent is an immunosuppressant. Immunosuppressants include calcineurin inhibitors such as cyclosporine or ascomycin, cyclosporine A (NEORAL®), FK506 (tacrolimus), pimecrolimus, mTOR inhibitors such as rapamycin or its derivatives such as sirolimus (Rapamune®), everolimus (Certican®), temsirolimus, zotarolimus, biolimus-7, biolimus-9, rapalogs such as ridaforolimus, azathioprine, Campath 1H, SI P receptor modulators, such as fingolimod or analogues thereof, anti-IL-8 antibodies, mycophenolic acid or a salt thereof, such as the sodium salt, or a prodrug thereof, such as mycophenolate mofetil (Cellcept®), OKT3 (Orthoclone OKT3®), prednisone, ATGAM®, Thymoglobulin®, brequinar sodium, OKT4, T10B9.A-3A, 33B3.1, 15-deoxyspergualin, tresperimus, leflunomide ARAVA®, CTLAI-Ig, anti-CD25, anti-IL2R, basiliximab (Simulect®), daclizumab (Zenapax®), misorubine, methotrexate, dexamethasone, ISAtx-247, SDZ ASM 981 (pimecrolimus, Elidel®), CTLA4lg (abatacept), belatacept, LFA3lg, etanercept (sold as Enbrel® by Immunex), adalimumab (Humira®), infliximab (Remicade®), anti-LFA-1 antibody, natalizumab (Antegren®), enlimomab, gabilimomab, anti-thymocyte immunoglobulin, siplizumab, alefacept efalizumab, pentasa, mesalazine, asacol, codeine phosphate, benorylate, fenbufen, naprosyn, diclofenac, etodolac, indomethacin, aspirin, and ibuprofen.
[0175] Additional bioactive agents can be found in U.S. Patent Application Publication No. 2019 / 0076539, which is incorporated by reference in its entirety.
[0176] Method of preparation The ARRDC1 fusion protein disclosed herein can be prepared by methods known to those skilled in the art.For example, ARRDC1 fusion protein can be produced genetically or chemically.Provided herein is a method for preparing arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicle (ARMM), comprising (a) culturing in a medium a host cell that contains a recombinant expression construct that encodes the ARRDC1 fusion protein disclosed herein under the control of a heterologous promoter; and (b) recovering ARMM from the medium.
[0177] In some embodiments, the host cell has a reduced expression level of ubiquitin ligase compared to a wild-type host cell. In some embodiments, the host cell is genetically engineered to have a reduced expression level of ubiquitin ligase compared to a wild-type cell. In some embodiments, the expression of ubiquitin ligase in the host cell is reduced or inhibited by antisense oligonucleotide (ASN) technology, RNA interference (RNAi) technology such as small interfering RNA (siRNA) or short hairpin RNA (shRNA), or gene editing tools known to those skilled in the art, such as CRISPR / Cas9 or zinc finger nuclease technology. In some embodiments, the expression of ubiquitin ligase in the host cell is reduced or inhibited by small molecule inhibitors known to those skilled in the art. In some embodiments, the activity of ubiquitin ligase in the host cell is reduced or inhibited. In some embodiments, the activity of ubiquitin ligase in the host cell is reduced or inhibited by small molecule inhibitors known to those skilled in the art. In some embodiments, the amount or activity of ubiquitin ligase expressed in the host cell is minimal so as not to substantially prevent the production of ARMM in the host cell. In some embodiments, the host cell lacks ubiquitin ligase. That is, the expression level of ubiquitin ligase cannot be detected by tools available in the art. In some embodiments, the host cell lacks at least one ubiquitin ligase. In some embodiments, the host cell lacks one or more ubiquitin ligases. The ubiquitin ligase may be selected from the group consisting of HECW2, HECW1, WWPL, WWP2, NEDD4-1, NEDD4-2, NEDD4L, SMURFL, SMURF2, SMURF1, ITCH, NEDL1, and NEDL2.
[0178] In some embodiments, the host cell has a reduced expression level of the target protein compared to a wild-type host cell. In some embodiments, the host cell is genetically engineered to have a reduced expression level of the target protein compared to a wild-type cell. In some embodiments, the expression of the target protein in the host cell is reduced or inhibited by antisense oligonucleotide (ASN) technology, RNA interference (RNAi) technology such as small interfering RNA (siRNA) or short hairpin RNA (shRNA), or gene editing tools known to those skilled in the art, such as CRISPR / Cas9 or zinc finger nuclease technology. In some embodiments, the expression of the target protein in the host cell is reduced or inhibited by small molecule inhibitors known to those skilled in the art. In some embodiments, the amount of the target protein expressed in the host cell is minimal so as not to substantially prevent the production of ARMM in the host cell. In some embodiments, the host cell lacks the target protein. That is, the expression level of the target protein is not detectable by tools available in the art.
[0179] How to degrade proteins and alter gene expression In some aspects, the present disclosure provides a method for degrading a target protein in a target cell, comprising contacting the target cell with an ARMM disclosed herein. The target protein can be any of the target proteins disclosed herein.
[0180] In some aspects, the present disclosure provides a method for altering the expression of at least one gene, comprising contacting target cells with the ARMM disclosed herein.The at least one gene can be any gene that is directly or indirectly controlled by the target protein that is degraded by the ARMM disclosed herein.
[0181] By contacting the target cells with the ARMM, there is no need to worry about cell permeability, which is often an issue with direct administration of fusion proteins. Additionally, there is a reduced risk of immune response to the fusion protein when delivered in an ARMM as opposed to when administered directly. In some embodiments, the target cell is a mammalian cell. In some embodiments, the target cell is a human cell. In some embodiments, the target cell is a stem cell. In some embodiments, the target cell is a cell in vitro or ex vivo, and the method comprises administering the ARMM to the cell in vitro or co-culturing the target cell with a microvesicle-producing cell in vitro. In some embodiments, the target cell is a cell in a subject, and the method comprises administering a microvesicle or a microvesicle-producing cell to the subject. In some embodiments, the subject is a mammalian subject. In some embodiments, the subject is a human subject. In some embodiments, the target cell is a pathological cell. In some embodiments, the target cell is a cancer cell. In some embodiments, the microvesicle includes a targeting agent that selectively binds to an antigen of the target cell. In some embodiments, the antigen of the target cell is a cell surface antigen. In some embodiments, the targeting agent is a membrane-bound immunoglobulin, an integrin, a receptor, a receptor ligand, an aptamer, a small molecule, or a fragment thereof.
[0182] All references and publications cited herein are hereby incorporated by reference.
[0183] The following examples are provided to further illustrate some embodiments of the present invention, but are not intended to limit the scope of the invention, and it will be understood that by their illustrative nature, other procedures, methodologies, or techniques known to those skilled in the art may be substituted. EXAMPLES
[0184] [Example 1] Degradation of mCherry by recruitment to ARRDC1 via fusion with single-domain antibody (sdAb) In this example, we show the reduction of mCherry protein levels by using ARRDC1 fusion protein containing a single domain antibody that binds ARRDC1 and mCherry (Figure 2A). 293T cells were co-transfected with 50 ng of mCherry expression construct and construct encoding ARRDC1 fusion protein. Cells were imaged for fluorescent signals 72 hours after transfection (Figure 2B). Lysates were harvested and analyzed by Western blotting (Figure 2C). The results reveal that the fusion protein can effectively promote the degradation of mCherry in a dose-dependent manner. The reduction of mCherry protein levels correlates with the increase of ARRDC1 fusion protein (Figure 2C).
[0185] [Example 2] Degradation of intracellular mCherry protein by ARRDC1 / sdAb fusion protein delivered by ARMM In this example, it is shown that intracellular mCherry protein levels are reduced by incubating target cells with ARMM particles payloaded with an ARRDC1 fusion protein containing an sdAb specific for mCherry protein.
[0186] ARMM particles payloaded with ARRDC1 / GFP fusion protein or ARRDC1 / anti-mCherry sdAb fusion protein were produced by culturing suspension-adapted cell lines derived from HEK293 cells (ThermoFisher) stably transfected with expression constructs encoding the relevant fusion protein. Additionally, ARMM payloaded with "pseudotype" ARRDC1 / anti-mCherry sdAb fusion protein was produced by cells engineered to overexpress vesicular stomatitis virus G protein (VSV-G). ARMM particles were produced by culturing the relevant cell lines in shaker flasks, harvesting conditioned media, and collecting, concentrating, and purifying ARMM particles by centrifugation to remove cellular debris, followed by ultrafiltration / diafiltration (UF / DF) using transverse flow filtration (TFF) using 50 nm pore hollow fiber filtration cassettes.
[0187] Adherent HEK293T target cells were seeded and transfected with 50 ng of mCherry expression construct described in Example 1, cultured for 1 day, and then replated. Approximately 6 hours later, 1x10 6 ARMM was added and the target cells were cultured for 2 days. An additional 1x10 6 of ARMM was added to the cultures and the cells were cultured for an additional 2 days, after which the cells were harvested and whole-cell extracts were prepared for Western blotting. One set of negative control target cells was treated with vehicle (phosphate-buffered saline, PBS) and a second set of negative control target cells was untreated.
[0188] Western blots were stained with anti-GAPDH (gel / blot loading control), anti-ARRDC1, and anti-mCherry. As shown in Figure 8, mCherry levels in target cells were not affected by the negative control (lanes 1 and 5) but were reduced by the ARRDC1 / anti-mCherry sdAb fusion protein delivered in ARMM, especially the VSV-G pseudotyped ARMM particles.
Claims
1. an arrestin domain-containing protein 1 (ARRDC1) protein or a variant thereof; A non-enzymatic targeting domain that recruits target proteins An ARRDC1 fusion protein comprising:
2. The ARRDC1 fusion protein of claim 1 , wherein the targeting domain is fused to the C-terminus of the ARRDC1 protein or its variant.
3. The ARRDC1 fusion protein according to any one of claims 1 to 2, wherein the ARRDC1 protein or its variant is fused to the targeting domain by a linker.
4. The ARRDC1 fusion protein according to any one of claims 1 to 3, wherein the ARRDC1 protein or variant thereof comprises at least two PPXY motifs.
5. The ARRDC1 fusion protein of claim 4, wherein the at least two PPXY motifs are different.
6. The ARRDC1 fusion protein of any one of claims 1 to 5, wherein the non-enzymatic targeting domain comprises an interaction domain.
7. The ARRDC1 fusion protein of claim 6 , wherein the interaction domain comprises a non-enzymatic protein-binding peptide.
8. The ARRDC1 fusion protein of any one of claims 1 to 7, wherein the target protein is a transcription factor, a tumor promoter or a protein product of an oncogene, a developmental regulator, a growth factor, a metastasis promoter, an anti-apoptotic protein, a membrane-associated protein, a transmembrane receptor, an enzyme, a nuclease, a recombinase, or a reprogramming factor.
9. The ARRDC1 fusion protein of any one of claims 1 to 8, wherein the non-enzymatic targeting domain comprises an intrabody.
10. The ARRDC1 fusion protein of claim 9, wherein the intrabody comprises a single domain antibody (sdAb).
11. 11. The ARRDC1 fusion protein of claim 10, wherein the sdAb is a camelid single domain.
12. The ARRDC1 fusion protein of any one of claims 1 to 11, wherein the end of the non-enzymatic targeting domain is fused to at least one additional PPXY motif.
13. The ARRDC1 fusion protein of claim 12, wherein the termini of the non-enzymatic targeting domain are fused to at least two additional PPXY motifs.
14. The ARRDC1 fusion protein of claim 13, wherein the at least two additional PPXY motifs are different PPXY motifs.
15. The ARRDC1 fusion protein of any one of claims 1 to 14, wherein the non-enzymatic targeting domain is fused to an Fc region of an antibody.
16. The ARRDC1 fusion protein of claim 15, wherein the non-enzymatic targeting domain or the Fc region of an antibody is fused to an RNA binding protein.
17. The ARRDC1 fusion protein of claim 16, wherein the RNA binding protein is a tat protein.
18. 18. The ARRDC1 fusion protein of claim 17, wherein the tat protein is an HIV tat protein or a BIV tat protein.
19. The ARRDC1 fusion protein of claim 1 , wherein the targeting domain comprises a binding aptamer.
20. The ARRDC1 fusion protein of any one of claims 1 to 19, wherein the targeting domain is fused to a ubiquitin ligase.
21. The ARRDC1 fusion protein according to any one of claims 3 to 19, wherein the linker is a cleavable linker.
22. The ARRDC1 fusion protein of claim 20 , wherein the cleavable linker comprises a protease cleavage site.
23. The ARRDC1 fusion protein of claim 22, wherein the protease cleavage site is a furin cleavage site.
24. The ARRDC1 fusion protein of claim 22, wherein the protease cleavage site is a viral cleavage site.
25. 24. The ARRDC1 fusion protein of claim 23, wherein the viral cleavage site comprises an HIV-1 protease cleavage site, a tobacco etch virus (TEV) cleavage site, or another cleavage site recognized by a viral protease.
26. The ARRDC1 fusion protein of claim 21 , wherein the cleavable linker is a photocleavable linker comprising a photocleavable protein or a fragment thereof.
27. The ARRDC1 fusion protein according to any one of claims 1 to 26, wherein the photocleavable linker comprises the photocleavable protein PhoCl1 or a fragment thereof.
28. The ARRDC1 fusion protein of any one of claims 26 to 27, wherein the photocleavable linker comprises a protein or protein fragment derived from PhoCl1.
29. The ARRDC1 fusion protein of claim 20, wherein the ubiquitin ligase is a ubiquibody.
30. 30. The ARRDC1 fusion protein of claim 29, wherein the ubiquibody is CHIP (carboxyl-terminal of Hsc70 interacting protein) or a fragment thereof.
31. The ARRDC1 fusion protein of claim 1 , wherein the non-enzymatic targeting domain comprises a ubiquitination-specific antibody domain.
32. The ARRDC1 fusion protein of any one of claims 1 to 31, wherein the ARRDC1 protein or variant thereof comprises a FLAG tag.
33. The ARRDC1 fusion protein of claim 32, wherein the FLAG tag comprises the sequence DYKDDDK (SEQ ID NO: 90).
34. (i) a lipid bilayer; (ii) an arrestin domain-containing protein 1 (ARRDC1) fusion protein or a variant thereof according to any one of claims 1 to 33; ARRDC1-mediated microvesicles (ARMM) containing:
35. 35. The ARMM of claim 34, further comprising a fusion RNA, said fusion RNA comprising (i) a binding RNA sequence that binds to said RNA binding protein, and (ii) an expressed sequence encoding a ubiquitin ligase.
36. 36. The ARMM of claim 35, wherein the RNA sequence is a TAR sequence.
37. 37. The ARMM of claim 35 or 36, wherein the ubiquitin ligase is Trim21.
38. A nucleic acid construct encoding an ARRDC1 fusion protein according to any one of claims 1 to 33.
39. A microvesicle-producing cell comprising a recombinant expression construct encoding the ARRDC1 fusion protein according to any one of claims 1 to 33 under the control of a heterologous promoter.
40. The microvesicle producing cell of claim 39, further comprising a recombinant expression construct encoding a fusion RNA under the control of a heterologous promoter, the fusion RNA comprising (i) a binding RNA sequence that binds to the RNA-binding protein, and (ii) an expression sequence encoding a ubiquitin ligase.
41. 41. The microvesicle-producing cell of claim 40, wherein the RNA sequence is a TAR sequence.
42. The microvesicle-producing cell according to claim 41 , wherein the ubiquitin ligase is Trim21.
43. A method for degrading a target protein, comprising contacting a target cell with a microvesicle according to any one of claims 34 to 37.
44. A method for altering the expression of at least one gene, comprising contacting a target cell with a microvesicle according to any one of claims 34 to 37.
45. 1. A method for preparing arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (ARMMs), comprising: (a) culturing in a medium a host cell comprising a recombinant expression construct encoding an ARRDC1 fusion protein according to any one of claims 1 to 33 under the control of a heterologous promoter; and (b) recovering the ARMM from the host cell or the medium. The method includes:
46. 46. The method of claim 45, wherein the host cell has a reduced expression level of ubiquitin ligase compared to a wild-type host cell.
47. 47. The method of claim 46, wherein the host cell is deficient in the ubiquitin ligase.
48. 48. The method of any one of claims 45 to 47, wherein the host cell has a reduced expression level of the target protein compared to a wild-type host cell.
49. 49. The method of claim 48, wherein the host cell is deficient in the target protein.
